CA2036031A1 - Near infrared diagnostic method and instrument - Google Patents
Near infrared diagnostic method and instrumentInfo
- Publication number
- CA2036031A1 CA2036031A1 CA002036031A CA2036031A CA2036031A1 CA 2036031 A1 CA2036031 A1 CA 2036031A1 CA 002036031 A CA002036031 A CA 002036031A CA 2036031 A CA2036031 A CA 2036031A CA 2036031 A1 CA2036031 A1 CA 2036031A1
- Authority
- CA
- Canada
- Prior art keywords
- tissue
- wavelengths
- diseased
- instrument
- lambda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002405 diagnostic procedure Methods 0.000 title abstract 2
- 238000002835 absorbance Methods 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 25
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 150000001840 cholesterol esters Chemical class 0.000 claims abstract description 9
- 239000000835 fiber Substances 0.000 claims description 35
- 210000004204 blood vessel Anatomy 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 238000005286 illumination Methods 0.000 claims description 10
- 201000001320 Atherosclerosis Diseases 0.000 claims description 8
- 239000013307 optical fiber Substances 0.000 claims description 6
- 230000003287 optical effect Effects 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 238000002679 ablation Methods 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 238000013532 laser treatment Methods 0.000 abstract description 2
- 238000000862 absorption spectrum Methods 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 83
- 210000000709 aorta Anatomy 0.000 description 27
- 206010035148 Plague Diseases 0.000 description 11
- 241000607479 Yersinia pestis Species 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 210000004177 elastic tissue Anatomy 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 210000002460 smooth muscle Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000002308 calcification Effects 0.000 description 5
- 210000002808 connective tissue Anatomy 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 238000000608 laser ablation Methods 0.000 description 5
- 238000013147 laser angioplasty Methods 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 4
- 230000002327 eosinophilic effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000009966 trimming Methods 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 206010052273 Dystrophic calcification Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241001101998 Galium Species 0.000 description 1
- 241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241001415395 Spea Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010068149 Vessel perforation Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000009365 direct transmission Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940056932 lead sulfide Drugs 0.000 description 1
- 229910052981 lead sulfide Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- GGYFMLJDMAMTAB-UHFFFAOYSA-N selanylidenelead Chemical compound [Pb]=[Se] GGYFMLJDMAMTAB-UHFFFAOYSA-N 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 210000001604 vasa vasorum Anatomy 0.000 description 1
- HGCGQDMQKGRJNO-UHFFFAOYSA-N xenon monochloride Chemical compound [Xe]Cl HGCGQDMQKGRJNO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
- A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
- A61B5/0086—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters using infrared radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
- A61B18/22—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Couplings or hand-pieces therefor
- A61B18/24—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Couplings or hand-pieces therefor with a catheter
- A61B18/245—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Couplings or hand-pieces therefor with a catheter for removing obstructions in blood vessels or calculi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/1459—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters invasive, e.g. introduced into the body by a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00017—Electrical control of surgical instruments
- A61B2017/00022—Sensing or detecting at the treatment site
- A61B2017/00057—Light
- A61B2017/00061—Light spectrum
Abstract
NEAR INFRARED DIAGNOSTIC METHOD AND INSTRUMENT
ABSTRACT
There are disclosed an instrument and method for using near IR to discriminate between healthy and diseased tissue, using, e.g., a catheter and a spectrophotometer. Near IR is passed at certain wavelengths to suspected tissue, and reflected light is analyzed to determine the absorbance, and preferably the second derivative thereof. From identification of the absorption spectra of known diseased and known healthy tissue, a relation has been established to determine the following correlation equation for determining the predictive value of y:
y = Co + C1A(.lambda.1) + C2A(.lambda.2) wherein A(.lambda.1) + A(.lambda.2) are the second derivatives for the absorbance at the two selected wavelengths. For blood cholesterol esters and plaque, .lambda.1 is preferably 1714.5 ant .lambda.2 is preferably 1678.5 nm. Solving for the coefficients Co, C1 and C2, it has been shown that values of y less than -8.0 represent diseased tissue, which should be treated. Ablation laser treatment is described as one mode of treatment.
ABSTRACT
There are disclosed an instrument and method for using near IR to discriminate between healthy and diseased tissue, using, e.g., a catheter and a spectrophotometer. Near IR is passed at certain wavelengths to suspected tissue, and reflected light is analyzed to determine the absorbance, and preferably the second derivative thereof. From identification of the absorption spectra of known diseased and known healthy tissue, a relation has been established to determine the following correlation equation for determining the predictive value of y:
y = Co + C1A(.lambda.1) + C2A(.lambda.2) wherein A(.lambda.1) + A(.lambda.2) are the second derivatives for the absorbance at the two selected wavelengths. For blood cholesterol esters and plaque, .lambda.1 is preferably 1714.5 ant .lambda.2 is preferably 1678.5 nm. Solving for the coefficients Co, C1 and C2, it has been shown that values of y less than -8.0 represent diseased tissue, which should be treated. Ablation laser treatment is described as one mode of treatment.
Description
`~
2 ~ 3 ~
~ .
FI~LD QF 5 EE_I~VE~TION
The invention relates to an instrument and method that allow a ~pectrophotometer to di~t~nguish between healthy cells and diseaset cells, ant al-o to apparatus and a method of subsequently treating the identified diseased cells.
~ GRQU~D QE r~E-~y~IIQ~
As has been noted in several technical ~ournals recently, atherosclerosis is a leading cause of non-accidental teath in the ~nited States. -Because the two conventional treatments, bypass surgery and balloon angioplasty, have ~nown tisatvantages, laser angioplasty is being turned to ag a more effective therapeutic technique.
Even laser angioplasty has its problems, however. Chief of these iB the inability to quic~ly distinguish between "friend" and "foe", that i~, between healthy vascular tissue and the diseased plaque. Conventionally, transluminal illumination i8 teliveret to and subsequently received from tissues, such as by diffuse reflection or direct transmission, to itentify and tistinguish plaque from healthy tiosue. The same optics are then used to deliver therapeutic laser light to ablate diseased t~ssue.
In the past, illumination has used light in the near ~V region, and the detection has been based upon fluorescence. In some cases, the tetected fluorescence was of certain fluorophors claimet to exist in the plaque. Still others are said to detect the natural fluorescence of both plaque and healthy tissue, and compare the signal with preteterminet values that are sait to represent healthy tissue or plaque. Such a system is tescribed in ~.S. Patent No. 4,718,417 and in Lasers in ~yr~ery and_MEdicine, Vol. 9, page 109-116 (1989). The latter describes the following equation to determine a ~-callet LIF
- . ................. . ........... . :
.. . ~
, . , - . .. ~ . ...
20~6~
ratio for the comparison: LIF e CO ~ ClIF
cl3IF(~l3) ~ ~Bing 13 different wavelengths to detect the fluorescence.
In either case, there are disadvantaees in Cuch prior 8y8tems. First of all, the illumination uses near ~V light, which has very low penetration power of slightly less than 100 ~m thic~ness, "Optics of ~uman S~in", Journal of Investi~at~y~
ma~QlQ~y, Vol. 77, p. 13-19 (1981). To avoid 10 ablating the wrong (healthy) tissue, such detection techniques require the laser to also ablate only on that order. A thin layer of ablation means that the total removal time is prolonged, and more illumination and detection, and thus delay, is required to remove the same amount of diseased tissue. In any event, delays while double-chec~ing the site cannot be easily s~ipped - failure to identify tissue as healthy before ablating it with laser energy can lead to vessel perforation. The risk of such perforation is consiteret to be "the major impediment to ~afe ant effective laser angioplasty" in current technology, e~li g_Q5~
Vol. 27, No. 9, p. 1844 (May 1988). The delay ~ust mentionet is further aggravated when using 25 fluorescence for tetection - laser ablation light tents to tehydrate remaining plague, which in turn can quench the fluorophore. To avoit this, an operation may have to wait up to 10-20 minutes for sufficient rehydration to occur. Such a wait is intolerable, when several ablative "blasts" are neetet to get through the plaque 100 ~m at a time.
Secnnt, the inability to tetect deep tissues has a further problem in that it cannot detect, until it is too late, that ~11 of the vascular wall at a 35 particular point has been convertet to tiseased tissue. That is, even the media tissue may be tiseaset, leaving only adventitia unterneath it.
., . . .: :; . . ~
., . : .;.. .. . ... ... .
;i :`: :~ . ; ~
.~ ~
2~3~3~
That however can have a thickness of only 100 ~m.
Since the ablation removal conventionally i~ up to about 100 ~m, the system that can "oee" only less than 100 ~m may end up ~eeing 80 ~m of plaguc and 5 20 ~m of atventitia, identify it as pr~marily plaque, and untesirably ablate away all but 80 ~m of the vascular wall.
Third, another difficulty e~i~ts in relying on fluorescence of plague - not all plaque is 10 homogeneous; nor do all diseased va8cular tissues fluoresce. In fact, plague has been found to contain some or all of the following: lipids, connective tissues, thrombus, necrotic tissues, mineralized deposits, smooth muscle cell tissues which have 15 proliferated from the vessel wall, as well as other constituents. Therefore, it is very difficult to be sure the fluorescence is complete enough and specific enough to permit the simultaneous multicomponent analysis capability that is an essential prerequisite 20 of an effective and safe "smart" laser angioplasty system. That is, many plague constituents "look li~e" other healthy body tissues. For e~ample;
platelets that deposit onto the surface of an artery ~such as in response to a ~mall, naturally occurring 25 injury in the arterial wall) can exute ~rowth factors which will cause the healthy smooth muscle tissues of the vascular wall to grow into the arterial lumen.
Such occlusive tissueg are li~ely to look no different from those smooth muscle tissues which make 30 up the media - the thic~est element of the vascular wall. Because healthy tissues can appear in "unhealthy" states, such "tiseased" tissues are very difficult to identify and discriminate from similar healthy tissues by using fluorescence.
Fourth, there occasionally arise some conditions that produce a thin surface film ~uch as lipid deposits on the healthy tissue that ap~ear to ",,, ; ~ ~
2~36~3.~
be plague, but in fact are not because underneath the very thin film (about 50-100 ~m) i8 healthy tissue. A discrimination system using near UV
illumination and fluorescence detection c~n ~ery S easily misinterpret cuch conditions, leading to dangerous attac~ on healthy tissue. Such attac~s can produce acute responses such as a clot. An e~ample of such a condition follows hereinafter.
Examples of prior art patents using the near 10 ~V illumination and detection of fluorescence a~
described above, ~1BO include ~.S. Patent NOB. 4,641,650. Some ~uch prior art techniques rely on the addition of a dye to preferentially "mar~"
plague. ~owever, dyes are inherently a systemic 15 foreign agent, subject to ris~ and governmental regulation. Accordingly, dyes are to be avoidet if possible.
Non-UV laser light h~ been used to examine tissue to identify abnormal conditions. For esample, 20 ~.S. Patent No. 4,449,535 teaches the use of a dye laser operating at a wavelength of 805 nm, the region of the very-near-infrared. The difficulty with that ~ind of detection system is two-folt: i) the wavelength of 805 nm is incapable of detecting two 25 ~ey materials of plaque in blood vessel~, name~y cholesterol esters and calcification, and ii) tyes for such dye lasers are not suitable for operating in wavelengths determined by the instant invention to be more appropriate for cholesterol esters and 30 calcification.
~ et another example of the use of non-~Y
light for disease detection is described in ~.S.
Patent No. 4,509,522. This describes the use of mid-infrared lasers operating at 5130 nm, to detect 35 the absorption band of carbon monoxide (column 2, line 39). Such radiation is said to be carriet over a fiber optic, if the exposure occurs at location~
: - .
- . ~, .. ... .
remote from the s~in. This technigue also ~uffers two disadvantages: i) the 5130 nm wavelength, although ~uitable for CO, is not ~uitable for the detection of the primary plaque components ~n - -5 atherosclerosis (chole8terol esters and calcification); and ii) there is no non-to~ic fiber optic ~nown to man that will transmit 5130 nm ratiation.
Thus, prior to this invention there has been 10 a need for a quic~, yet accurate laser angioplasty instrument that allows for immediate identification of diseased ti~sue from healthy tissues before firing the laser, particularly such instrument capable of treating atherosclerosis. Such an ~nstrument i8 desired for its ability to identify and discriminate between all types of diseased and non-diseased tis6ues, of which atherosclerosis is but one type.
SUMM~Ry OF T~E INVEN~Q~
We have constructed an instrument and a 20 method that solve the above-noted problems.
More 8pecifically, in accord with one aspect of the invention, there is provided an instrument for tetecting and treating selectively, diseased portions of body tissue, the instrument comprising a) means for illuminating portions of the body tissue with light energy of pretetermined wavelengths selected from the range of between about 1000 and 2500 nm, the predetermined wavelengths being effective to be selectively absorbed by a pre6elected component of the tissue, b) means for collecting the light at the predetermined wavelengths that i8 not absorbed by the tissue portions, c) means for examining the amounts of absorbance of the light by the illuminated body tissue as determined from the collected light, and ~. . . - :
.. . . , ~ ;
. . , ~ , . . .
~3~
d~ discriminating means for discriminating one illuminatet tissue component from another illuminated tissue component at the wavelengths, whereby certain illuminated portion- of the 5 body tissue are identified and located as being diseased.
In accord with another aspect of the invention, there is provited a surgical instrument - suitable for atherosclerosis treatment, comprising a 10 catheter having a distal ent constructet to penetrate a blood vessel, a pro~imal end constructed to remain ~utside the blood vessel, and a body portion connecting the ends, the ends and body portion including at least one optical fiber capable of delivering from one end, illumination light of desired wa~elengths, the distal end further including optical means for transmitting and receiving light energy from the fibers to a blood vessel, and from the illuminated blood vessel to the fibers, respectively; the proximal end further including a) means for generating light energy at predetermined wavelengths between about 1660 nm and about 1740 nm, b) means for telivering the generatet energy to the at least one fiber, c) means for detecting the amount 25 of such generated energy that is not absorbed by illuminated tissue in a blood vessel and d) means for discriminating illuminated healthy tissue from illuminated diseased tissue at the wavelengths, the instrument further including treating means for 30 selectively treating only the illuminated diseased ti~sue as determined by the discriminating mean~.
In accord with yet another aspect of this invention, there is provided a method of detecting certain tissue in body tissue, comprising the steps of a) illuminating portions of the body tissue with light energy of predetermined wavelengths selected from the range of between about 1000 and . , , - ... .; .. .. ~ ~ ,., - ..
~3~3~
_,_ about 2500 nm, the predetermined wavelengths being effective to be selectively absorbet by a preselectet component of the tissue, b) collecting the light at the 5 predeterminet wavelengths that is not ab80rbed from the tissue portions, c) examining the amounts of absorbance of the light as determined $rom the collected amounts not absorbed by the illuminated body tissue, and d) discriminating one illuminated tissue component from another illuminated tissue component at the wavelengths, whereby certain illuminated portions of body tissue are identifiet ant located.
Therefore, it i8 an advantageous feature of the invention that an instrument and method are provided for detecting by illumination, diseased tissue from healthy tissue, using a portion of the spectrum that i8 more able to penetrate tissue to 20 determine the true condition of the ti8sue.
It is a related advantageous feature of the invention that such instrument and method pcrmit treatment of identified diseaset tissue in conjunction with the same insttument uset for identification, at a more rapid rate than is possible using UV spectra for detection.
Although the method and instrument are particularly suited for diagnosis and treatment of atherosclerosis, it also lends itself to other disease detection as an advantageous feature.
Other advantageous features will become apparent upon reference to the following Detailed Description, when read in light of the attached drawings.
BRIEF_DESCRI~TION OF T~E_~RA~LNQ5 Fig. lA i~ a fragmentary, partially schematic illustration of the instrument of the invention;
. . , I . . .
,-. .
.
Fig. lB i8 a fragmeDtary, partially schematic enlarged illu~tration of the ~witch of Fig. lA:
Fig. 2 i~ a fragmentary elevational view, 5 partially in section, of the distal end of the catheter;
Fig. 3 iB a fragmentary elevational view of such di8tal end in an artery, illu8trating its manner of use;
Fig. 4 i8 an absorbance plot representative of the absorbance obtained by the spectrophotometer of the invention, of four different samples of human aorta, viewed ex vivo;
Fig. 5 is a plot of the second terivative of 15 absorbance for two different human aorta samples;
Fig. 6 is a loading plot of two principle component a~es for 42 different human aorta samples;
Fig. 7 is a regression plot of predicted versus actual data for distinguishing diseased versus 20 healthy data, using two NIR wavelengths for comparison;
Fig. 8 is a fragmentary schematic ~ection view of an artery that can be diagnosed and treated in accordance with the invention, the sectioning of 25 which is intended to represent tissue;
Fig. 9 is a representative schematic illustration of the reflection spectra that is carried by fibers 15 of the catheter used by this invention; and Fig. 10 i8 a plot similar to that of Fig. 5, but illustrating different results for a different sample.
DES~FIPTION OF T~ PREFERRED EMBODIMENI~
The description that follows hereinafter 35 particularly adtresses the preferred embodiment wherein atherosclerosis in all ~inds of blood vessels i8 diagnosed and treated, using reflected wavelengths particularly effective in being absorbed by disease X~3~
_9_ 8tates of uch vessels, such as plague, and ueing an ablation laser for treatment. ~owever, in determining the amount of light absorbance by the illuminated body tissue, any mode of light collection - - 5 can be used. The preferred mode is reflection, in which the light used to illuminate iB reflectet bac~
at the same wavelengths used to illuminate. The amount of absorbance then is the amount of reduction in am~litude that the reflected light represents, and 10 this amount can be shown to vary characteristically with the type of tissue present. That is, when illuminating with near infrared radiation at wavelengths between about lOOO and 2500 nm, markedly different absorption curves are generated depending 15 on whether the tissue is diseased or healthy. This is considered to be true generally, but for purposes of this invention, it will be tescribed particularly for the identification of plaque in cardio-vascular tissue, the preferred embodiment. That is, the 20 digeaged component to be identified is preferably plaque, particularly as it is to be found in a blood vessel of any type.
Also, the preferred embodiment features the use of absorbance values at two selected wavelengths, 25 using a spectrophotometer that examines a broad NIR
range. In addition, however, a simplified spectrophotometer can be used in the invention to examine only those selected wavelengths and/or their first and second derivatives, that are found to be 30 useful for a particular disease condition.
The more general nature of the invention is to ma~e the discrimination between two different ~inds of tissue~, and more specifically, between any diseased state and the healthy tissue associated 35 therewith. Once the diseased tissue i8 identified and discriminated from healthy tissue, a further aspect of the invention, which ie nevertheless ~ . ., ~ , .
r - 2~3~3~
optional, is to treat that diseased tissue. Any mode of treatment is suitable, but only la8er ablation, the preferred embodiment, is discussed herein. If the disease condition i8 something other than plaque, 5 it i8 a simple matter to scan the diseased tis~ue of choice, and detect the near IR that is reflected to tetermine the characteristic wavelengths that are peculiarly different, in their absorption, from the wavelengths absorbed by the healthy ti~sue. The 10 principle component analysis procedure and multiple linear regression hereinafter described, e.g., for Figs. 6 and 7, is applied for, e.g., a number of selected wavelength6 suited to this disease, within the range of 1000 to 2500 nm, and an uncertainty zone 15 (Fig. 7) iB plotted as ha8 been done hereinafter, but based upon the wavelengths suited to this particular disease.
Referring now to Fig. lA ~ lB, an instrument 10 constructed in accord with the invention comprises 20 a catheter 12 to be placed into a patient body, e.g., an artery, a light source portion 20, a detector portion 50, control means 58 and a laser 60.
Catheter 12 has proximal portion 14 comprising a plurality of several, e.g. 7, optical fibers 15, 25 carrying light to a distal end 16 (described hereafter) and returning reflected light to portion 50.
Light source portion 20, Fig. lA, can feature any convenient source of radiation, selected 30 to include significant radiation in the range of from 1000 to 2500 nm. For example, it can comprise a lamp 22, reflector 24, optical focusing elements 26 and a beam splitter 28, BO that the light image reflects off a second beam splitter 30 through a switch 32 to 35 illuminate indivitual fibers 15 of catheter 12, Fig.
lB.
Switch 32 i8 an optical switch, which conventionally provides an intermediate fiber optic , 2~3~3~
34 that i8 anchored at one end 36, with an opposite end 38 that i8 magnetically moved rapidly to the various positions, shown in phantom, that align with ends 140f fibers 15. Such a switch iB available -5 from York.
Detector portion 50 comprises a lens 52, n optical fibers 55 carrying n bifurcated beams 1 2 . 3 from lens 52, and a spectrophotometer 56. Inside the spectrophotometer is a set of n ters Fl, F2 Fn and a corresponding set of n photodetectors 54, for scanning each of the optical fibers of catheter 12 at the wavelengths selected by filters Fl, F2. . . Fn. Suitable photodetectors include germanium, lead sulfide, lead selenide or indium galium arsenide detectors. The value of n for the detectors, filters, and fibers 55 is dependent on the number of wavelengths needed, as discussed hereinafter. If n > > 19, then the filters preferably are replaced with a dispersive device such as a grating or prism, as in a monochromator or spectrograph.
Any spectrophotometer 56 is useful for this purpose. The output of spectrophotometer 56 is analyzed by control means 58, that includes computing means of any suitable type to do the numeric analysis described below and to solve an eguation, notet hereinafter. Control means 58 in turn provides a control signal to laser 60, to fire a laser beam along any one of the optic fibers 15 that is 30 determined to be viewing a diseased site, but only .
along such fibers. Switching mechanism 32 is used to switch the laser to an appropriate fiber, which can be the same switching mechanism as described for illuminating each of the optic fibers 15 with light from source 22.
As shown in Fig.2, distal end 16 comprises a transparent shield 62 adjacent the focusing ends 64 ~ ~ 3 ~
of fiber optics 15. Such ends deliver a cone of light, 70, Fig. 3, that is divided into separate cones 72a, 72b,...up to 72m, or m cones for m fibers. Preferably, m = 7. Laser light for treatment also is confined to each cone 72a, etc. but the depth of treatment can be, and preferably is, less deep, as shown by the shaded portion. Thus, for the NIR range of 1000 to 2500 nm, penetration depth for examination is from about l mm to about 5 mm, whereas treatment depth is preferably from about 5 ~m to about lO0 ~m. However, treatment depth can be linearly scaled as degcribed hereafter.
The same cones of emitted light 72a...72m represent the tissue that reflects back the emitted light, except to the extent it is absorbed.
Preferably control means 58 u~es a disease index equation regressed to fit large numbers of patient data 80 as to be predictive from the absorbance, or the first or second derivative of absorbance, at the minimum number of wavelengths within the range of 1000 to 2500 nm, needed to discriminate tissue. That is, a spectrophotometer 56 can read absorbance at wavelength data points adjacent to each of the preferred wavelengths, to allow a first and/or a second derivative to be calculated and compared against a threshold value.
Thus, a useful di~ease equation index, i~ preferably of the form Y + Cl A('Al) + C2 A(~2) + cn A(~n) where A(~i) is the absorbance, or the first or second derivative of the absorbance, depending upon the confidence levels of the raw data - that i8, how likely is it that a particular spot illuminated by the catheter i8 totally healthy, or totally diseased. The value of n is determined as the minimum number needed to assure accurate and reliable ,, ., ~,. ;..-. ,. . , - ., . ., . . . -., , . , ~, .~ ".. , ..~- .. .....
. . i , . . - . .
2 ~
prediction. This in part depends upon the aperture of the illuminating beam and thus the area of the tissue examined. The larger the area, the less likely it is that the tissue is tot~Lly healthy or - 5 unhealthy. Thus, if the diameter of the area viewed is no larger than about 100 ~m, it is believed that it iB li~ely that A(~i) can be just the raw absorbance, instead of a derivative, if there i8 no baseline shift.
Referring again to Equation (1), this equation has been derived as follows:
The absorbance of a large number of healthy and diseased tissues is plotted against a continueum of wavelengths between the values of 1000 and 2500 nm. The example charted in Fig. 4 shows only four such curves, where 80 and 82 are healthy tissue of a blood vessel, and 90 and 92 are from diseased tissue characterized as plaque. Because each sample can have a baseline shift that is extraneous to the characteri~tic absorbance, the first and second derivative is preferably taken for all the data.
Fig. S illustrates an example of the second derivative ta~en from the absorbances of aorta from only two different human patients. Curve 100 is a disease curve (representing plaque), and curve 102 s8 a healthy curve. It will be readily apparent that the region between cross-over points is particularly useful, but only where the curves are witely divergent. From the graph of Fig. 5 it is apparent that thig defines the region of from about 1660 nm to about 1690 nm, and then from about 1700 nm to about 1740 nm, or more broadly, from about 1690 nm to about 1740 nm. Even the region of 1690-1700 is useful, unless it turns out to be the cross-over point for ~11 the data being considered, which is not the case for plaque in human aorta.
Next, numerical analysis is done via the standard technique of ~principle component analysis~
. . - . . .
1~ . ,. ; ,; -... . ' i ~ .. , ~ .
1 . . . ' ' ''~. ~ '' ~' . ' '~ ` ' ' '' ' . I .
.: ~ ': :: ' ' .
2 ~ ~ ^3~ ~
(PCA) as described, for example, in "The ~se of Principal Components in the Analysis of Near-Infrared Spectra", Cowe et al, Analytical Chemistry, Vol. 39 (1985), pp. 257-266.) Such a process involves plotting values of the absorbance, or the first or second derivatives of the absorbance measured at, or calculated for, for example, two wavelengths, in at least two and up to n dimensional space, using ~nown PCA mathematics to determine the representative axes of greatest variance in the values (hereinafter, data points). As a result, principle components axis T
is the axis of the greatest variation in the data, regardless of the cause of that variation. Axis T2 is chosen, ~ig. 6, to represent the next greatest axis of variation, and typically represents some variance factor other than that plotted on Tl.
The purpose of the exercise is to determine a) what wavelengths, if any, correlate to a maximum digtinction between tissue samples, and b) whether such distinctions correlate to disease conditions.
In Fig. 5, one can see that a plausible set of Lambda~s would be, e.g. 1678 nm and 1714 nm.
However, because many samples and many curves are reguired to pic~ the best wavelengths, the human eye cannot readily identify the best wavelengthY.
Instead, when the Tl scores from the PCA analysis are obtained, a new plot, Fig. 7, is prepared.
Multiple linear regression on all the sample spectra, using the Tl scores as input data and using a 95%
confidence limit, provides a fit to the data. The predicted values are shown on the y-axis. For plaque in human aorta, n f ~n need only be equal to 2.
Using this data, the equation is solved to determine the coefficients, and the equation then for line 200 ig found to be:
(2) y = -158.77 - 3.72 x 106 A(~l) +
2.03x106 A(~2), for ~1 = 1714 nm and ~2 = 1678 nm.
' ' ~ ,', ~, - 2~3~
Next, all the samples used in analysis are examined by a skilled pathologist, to determine which samples are healthy and which are diseased. For plaque in a blood veæsel, containing cholesterol esters and calcification as the primary distinguishing components, we have found that the graph of Fig. 7 i6 in fact a plot discriminating diseased from healthy tisgue. Stated in other words, the principle component axis Tl has been found to be digtinguishing the samples based upon whether or not they are diseaged, as the primary distinguishing feature.
From this discovery, we have ascertained a threshold value of y which is a predictive of diseaged conditions. That value in Fig. 7 has been found to be any value of y less than -8Ø Thus, the instrument of this invention determines that plaque is present if and when the instrument determines that y < -8.0, using only the second derivatives of two wavelengths being read, for example, 1714 and 1678 nm. Both equation (2) and the threshold value of -~.0 are stored in control means 58.
It will be seen that there is a range, marked U for "uncertainty", Fig. 7, of values "y"
that is not predictive either way. Such values occur due in pa~t to the ability of the near infrared to penetrate through to healthy underlying tissues, Fig. 8, unlike W or visible diagnostic radiation used in the prior art. The actual boundaries for zone U were determined aæ follows: turing the examination of the tissue samples, it was determined that the bunch of "healthyl' samples that i8 closest to the closest diseased samples (Y) was bunch X.
These two bunches were bisected, which produces a Y
value of about -4.5. The highest boundary for zone U
was picked as that value just above healthy bunch X, namely a ~ value of about -1.0, and the same value of , . : . . .: ,.
- . , , .. :. .. . ; ; : : ,,, ;
203~3~
that increment (3.5) was then subtracted from the bisecting value of -4.5 to produce the other bountary -8Ø
Regarding the values on the y-axis of Fig.
7, the relative scale results from the difficulty in defining and quantifying what is a ~diseased state"
of the tissue. If a clear and descriptive definition of disease could be agreed upon, and if a method could be found for extracting the diseage components and quantifying them (percent weight or other form of chemical concentration), then the y-scale could be made absolute. The method proposed for using near IR
wavelengths for tissue discrimination described herein would remain the same, except that one would use the absolute y-scale. In absence of such definitions and data, however, the use of expert pathology and principle component analysis has allowed for a relative scale which can function to provide the advantages noted herein.
Regarding the treatment that is applied to the identified diseased tissue, a variety of treatments are possible and conventional. Any such treatment ~nown to be done via a catheter is useful with this invention. Preferred is surgical removal of the tissue, and most preferred i~ laser ablation.
Optionally, auxilliary features can also be included on the catheter (not shown). For example, the catheter can include expandable balloons either for positioning or treatment.
Regarding laser ablation, a wide variety of lasers 60 can be coupled to the optics of the laser to perform such ablation. Such lasers are well-known and detailed descriptions are not needed. The selection will depend partly on the desired result.
For example, pul~ed 308 nm xenon chloride excimer lasers can be used, and have been described, for example, in "Laser Ablation of ~uman Atherosclerotic : ~ :
2 ~ 3 ~
Plaque," J~ L-~oll. Ca~iol~, Vol. 5, pp. 929-933 (1985). Such a laser can be operated to remove 17 ~m of tissue per pulse.
Other useful lasers include any other~ that - 5 are heavily attenuated by tissues, such as Er:~AG or ~olmium:~AG.
The method of the invention will be readily apparent from the preceding. In brief, catheter 16, Fig. 1, is inserted into the patient's body at a 10 guitable site, and fed along the cardiovascular system to a suspected site. At the suspected site, the light ~ource of portion 20 is cycled through each of the optic fibers 15 to illuminate that spot, Fig.
~ .
FI~LD QF 5 EE_I~VE~TION
The invention relates to an instrument and method that allow a ~pectrophotometer to di~t~nguish between healthy cells and diseaset cells, ant al-o to apparatus and a method of subsequently treating the identified diseased cells.
~ GRQU~D QE r~E-~y~IIQ~
As has been noted in several technical ~ournals recently, atherosclerosis is a leading cause of non-accidental teath in the ~nited States. -Because the two conventional treatments, bypass surgery and balloon angioplasty, have ~nown tisatvantages, laser angioplasty is being turned to ag a more effective therapeutic technique.
Even laser angioplasty has its problems, however. Chief of these iB the inability to quic~ly distinguish between "friend" and "foe", that i~, between healthy vascular tissue and the diseased plaque. Conventionally, transluminal illumination i8 teliveret to and subsequently received from tissues, such as by diffuse reflection or direct transmission, to itentify and tistinguish plaque from healthy tiosue. The same optics are then used to deliver therapeutic laser light to ablate diseased t~ssue.
In the past, illumination has used light in the near ~V region, and the detection has been based upon fluorescence. In some cases, the tetected fluorescence was of certain fluorophors claimet to exist in the plaque. Still others are said to detect the natural fluorescence of both plaque and healthy tissue, and compare the signal with preteterminet values that are sait to represent healthy tissue or plaque. Such a system is tescribed in ~.S. Patent No. 4,718,417 and in Lasers in ~yr~ery and_MEdicine, Vol. 9, page 109-116 (1989). The latter describes the following equation to determine a ~-callet LIF
- . ................. . ........... . :
.. . ~
, . , - . .. ~ . ...
20~6~
ratio for the comparison: LIF e CO ~ ClIF
cl3IF(~l3) ~ ~Bing 13 different wavelengths to detect the fluorescence.
In either case, there are disadvantaees in Cuch prior 8y8tems. First of all, the illumination uses near ~V light, which has very low penetration power of slightly less than 100 ~m thic~ness, "Optics of ~uman S~in", Journal of Investi~at~y~
ma~QlQ~y, Vol. 77, p. 13-19 (1981). To avoid 10 ablating the wrong (healthy) tissue, such detection techniques require the laser to also ablate only on that order. A thin layer of ablation means that the total removal time is prolonged, and more illumination and detection, and thus delay, is required to remove the same amount of diseased tissue. In any event, delays while double-chec~ing the site cannot be easily s~ipped - failure to identify tissue as healthy before ablating it with laser energy can lead to vessel perforation. The risk of such perforation is consiteret to be "the major impediment to ~afe ant effective laser angioplasty" in current technology, e~li g_Q5~
Vol. 27, No. 9, p. 1844 (May 1988). The delay ~ust mentionet is further aggravated when using 25 fluorescence for tetection - laser ablation light tents to tehydrate remaining plague, which in turn can quench the fluorophore. To avoit this, an operation may have to wait up to 10-20 minutes for sufficient rehydration to occur. Such a wait is intolerable, when several ablative "blasts" are neetet to get through the plaque 100 ~m at a time.
Secnnt, the inability to tetect deep tissues has a further problem in that it cannot detect, until it is too late, that ~11 of the vascular wall at a 35 particular point has been convertet to tiseased tissue. That is, even the media tissue may be tiseaset, leaving only adventitia unterneath it.
., . . .: :; . . ~
., . : .;.. .. . ... ... .
;i :`: :~ . ; ~
.~ ~
2~3~3~
That however can have a thickness of only 100 ~m.
Since the ablation removal conventionally i~ up to about 100 ~m, the system that can "oee" only less than 100 ~m may end up ~eeing 80 ~m of plaguc and 5 20 ~m of atventitia, identify it as pr~marily plaque, and untesirably ablate away all but 80 ~m of the vascular wall.
Third, another difficulty e~i~ts in relying on fluorescence of plague - not all plaque is 10 homogeneous; nor do all diseased va8cular tissues fluoresce. In fact, plague has been found to contain some or all of the following: lipids, connective tissues, thrombus, necrotic tissues, mineralized deposits, smooth muscle cell tissues which have 15 proliferated from the vessel wall, as well as other constituents. Therefore, it is very difficult to be sure the fluorescence is complete enough and specific enough to permit the simultaneous multicomponent analysis capability that is an essential prerequisite 20 of an effective and safe "smart" laser angioplasty system. That is, many plague constituents "look li~e" other healthy body tissues. For e~ample;
platelets that deposit onto the surface of an artery ~such as in response to a ~mall, naturally occurring 25 injury in the arterial wall) can exute ~rowth factors which will cause the healthy smooth muscle tissues of the vascular wall to grow into the arterial lumen.
Such occlusive tissueg are li~ely to look no different from those smooth muscle tissues which make 30 up the media - the thic~est element of the vascular wall. Because healthy tissues can appear in "unhealthy" states, such "tiseased" tissues are very difficult to identify and discriminate from similar healthy tissues by using fluorescence.
Fourth, there occasionally arise some conditions that produce a thin surface film ~uch as lipid deposits on the healthy tissue that ap~ear to ",,, ; ~ ~
2~36~3.~
be plague, but in fact are not because underneath the very thin film (about 50-100 ~m) i8 healthy tissue. A discrimination system using near UV
illumination and fluorescence detection c~n ~ery S easily misinterpret cuch conditions, leading to dangerous attac~ on healthy tissue. Such attac~s can produce acute responses such as a clot. An e~ample of such a condition follows hereinafter.
Examples of prior art patents using the near 10 ~V illumination and detection of fluorescence a~
described above, ~1BO include ~.S. Patent NOB. 4,641,650. Some ~uch prior art techniques rely on the addition of a dye to preferentially "mar~"
plague. ~owever, dyes are inherently a systemic 15 foreign agent, subject to ris~ and governmental regulation. Accordingly, dyes are to be avoidet if possible.
Non-UV laser light h~ been used to examine tissue to identify abnormal conditions. For esample, 20 ~.S. Patent No. 4,449,535 teaches the use of a dye laser operating at a wavelength of 805 nm, the region of the very-near-infrared. The difficulty with that ~ind of detection system is two-folt: i) the wavelength of 805 nm is incapable of detecting two 25 ~ey materials of plaque in blood vessel~, name~y cholesterol esters and calcification, and ii) tyes for such dye lasers are not suitable for operating in wavelengths determined by the instant invention to be more appropriate for cholesterol esters and 30 calcification.
~ et another example of the use of non-~Y
light for disease detection is described in ~.S.
Patent No. 4,509,522. This describes the use of mid-infrared lasers operating at 5130 nm, to detect 35 the absorption band of carbon monoxide (column 2, line 39). Such radiation is said to be carriet over a fiber optic, if the exposure occurs at location~
: - .
- . ~, .. ... .
remote from the s~in. This technigue also ~uffers two disadvantages: i) the 5130 nm wavelength, although ~uitable for CO, is not ~uitable for the detection of the primary plaque components ~n - -5 atherosclerosis (chole8terol esters and calcification); and ii) there is no non-to~ic fiber optic ~nown to man that will transmit 5130 nm ratiation.
Thus, prior to this invention there has been 10 a need for a quic~, yet accurate laser angioplasty instrument that allows for immediate identification of diseased ti~sue from healthy tissues before firing the laser, particularly such instrument capable of treating atherosclerosis. Such an ~nstrument i8 desired for its ability to identify and discriminate between all types of diseased and non-diseased tis6ues, of which atherosclerosis is but one type.
SUMM~Ry OF T~E INVEN~Q~
We have constructed an instrument and a 20 method that solve the above-noted problems.
More 8pecifically, in accord with one aspect of the invention, there is provided an instrument for tetecting and treating selectively, diseased portions of body tissue, the instrument comprising a) means for illuminating portions of the body tissue with light energy of pretetermined wavelengths selected from the range of between about 1000 and 2500 nm, the predetermined wavelengths being effective to be selectively absorbed by a pre6elected component of the tissue, b) means for collecting the light at the predetermined wavelengths that i8 not absorbed by the tissue portions, c) means for examining the amounts of absorbance of the light by the illuminated body tissue as determined from the collected light, and ~. . . - :
.. . . , ~ ;
. . , ~ , . . .
~3~
d~ discriminating means for discriminating one illuminatet tissue component from another illuminated tissue component at the wavelengths, whereby certain illuminated portion- of the 5 body tissue are identified and located as being diseased.
In accord with another aspect of the invention, there is provited a surgical instrument - suitable for atherosclerosis treatment, comprising a 10 catheter having a distal ent constructet to penetrate a blood vessel, a pro~imal end constructed to remain ~utside the blood vessel, and a body portion connecting the ends, the ends and body portion including at least one optical fiber capable of delivering from one end, illumination light of desired wa~elengths, the distal end further including optical means for transmitting and receiving light energy from the fibers to a blood vessel, and from the illuminated blood vessel to the fibers, respectively; the proximal end further including a) means for generating light energy at predetermined wavelengths between about 1660 nm and about 1740 nm, b) means for telivering the generatet energy to the at least one fiber, c) means for detecting the amount 25 of such generated energy that is not absorbed by illuminated tissue in a blood vessel and d) means for discriminating illuminated healthy tissue from illuminated diseased tissue at the wavelengths, the instrument further including treating means for 30 selectively treating only the illuminated diseased ti~sue as determined by the discriminating mean~.
In accord with yet another aspect of this invention, there is provided a method of detecting certain tissue in body tissue, comprising the steps of a) illuminating portions of the body tissue with light energy of predetermined wavelengths selected from the range of between about 1000 and . , , - ... .; .. .. ~ ~ ,., - ..
~3~3~
_,_ about 2500 nm, the predetermined wavelengths being effective to be selectively absorbet by a preselectet component of the tissue, b) collecting the light at the 5 predeterminet wavelengths that is not ab80rbed from the tissue portions, c) examining the amounts of absorbance of the light as determined $rom the collected amounts not absorbed by the illuminated body tissue, and d) discriminating one illuminated tissue component from another illuminated tissue component at the wavelengths, whereby certain illuminated portions of body tissue are identifiet ant located.
Therefore, it i8 an advantageous feature of the invention that an instrument and method are provided for detecting by illumination, diseased tissue from healthy tissue, using a portion of the spectrum that i8 more able to penetrate tissue to 20 determine the true condition of the ti8sue.
It is a related advantageous feature of the invention that such instrument and method pcrmit treatment of identified diseaset tissue in conjunction with the same insttument uset for identification, at a more rapid rate than is possible using UV spectra for detection.
Although the method and instrument are particularly suited for diagnosis and treatment of atherosclerosis, it also lends itself to other disease detection as an advantageous feature.
Other advantageous features will become apparent upon reference to the following Detailed Description, when read in light of the attached drawings.
BRIEF_DESCRI~TION OF T~E_~RA~LNQ5 Fig. lA i~ a fragmentary, partially schematic illustration of the instrument of the invention;
. . , I . . .
,-. .
.
Fig. lB i8 a fragmeDtary, partially schematic enlarged illu~tration of the ~witch of Fig. lA:
Fig. 2 i~ a fragmentary elevational view, 5 partially in section, of the distal end of the catheter;
Fig. 3 iB a fragmentary elevational view of such di8tal end in an artery, illu8trating its manner of use;
Fig. 4 i8 an absorbance plot representative of the absorbance obtained by the spectrophotometer of the invention, of four different samples of human aorta, viewed ex vivo;
Fig. 5 is a plot of the second terivative of 15 absorbance for two different human aorta samples;
Fig. 6 is a loading plot of two principle component a~es for 42 different human aorta samples;
Fig. 7 is a regression plot of predicted versus actual data for distinguishing diseased versus 20 healthy data, using two NIR wavelengths for comparison;
Fig. 8 is a fragmentary schematic ~ection view of an artery that can be diagnosed and treated in accordance with the invention, the sectioning of 25 which is intended to represent tissue;
Fig. 9 is a representative schematic illustration of the reflection spectra that is carried by fibers 15 of the catheter used by this invention; and Fig. 10 i8 a plot similar to that of Fig. 5, but illustrating different results for a different sample.
DES~FIPTION OF T~ PREFERRED EMBODIMENI~
The description that follows hereinafter 35 particularly adtresses the preferred embodiment wherein atherosclerosis in all ~inds of blood vessels i8 diagnosed and treated, using reflected wavelengths particularly effective in being absorbed by disease X~3~
_9_ 8tates of uch vessels, such as plague, and ueing an ablation laser for treatment. ~owever, in determining the amount of light absorbance by the illuminated body tissue, any mode of light collection - - 5 can be used. The preferred mode is reflection, in which the light used to illuminate iB reflectet bac~
at the same wavelengths used to illuminate. The amount of absorbance then is the amount of reduction in am~litude that the reflected light represents, and 10 this amount can be shown to vary characteristically with the type of tissue present. That is, when illuminating with near infrared radiation at wavelengths between about lOOO and 2500 nm, markedly different absorption curves are generated depending 15 on whether the tissue is diseased or healthy. This is considered to be true generally, but for purposes of this invention, it will be tescribed particularly for the identification of plaque in cardio-vascular tissue, the preferred embodiment. That is, the 20 digeaged component to be identified is preferably plaque, particularly as it is to be found in a blood vessel of any type.
Also, the preferred embodiment features the use of absorbance values at two selected wavelengths, 25 using a spectrophotometer that examines a broad NIR
range. In addition, however, a simplified spectrophotometer can be used in the invention to examine only those selected wavelengths and/or their first and second derivatives, that are found to be 30 useful for a particular disease condition.
The more general nature of the invention is to ma~e the discrimination between two different ~inds of tissue~, and more specifically, between any diseased state and the healthy tissue associated 35 therewith. Once the diseased tissue i8 identified and discriminated from healthy tissue, a further aspect of the invention, which ie nevertheless ~ . ., ~ , .
r - 2~3~3~
optional, is to treat that diseased tissue. Any mode of treatment is suitable, but only la8er ablation, the preferred embodiment, is discussed herein. If the disease condition i8 something other than plaque, 5 it i8 a simple matter to scan the diseased tis~ue of choice, and detect the near IR that is reflected to tetermine the characteristic wavelengths that are peculiarly different, in their absorption, from the wavelengths absorbed by the healthy ti~sue. The 10 principle component analysis procedure and multiple linear regression hereinafter described, e.g., for Figs. 6 and 7, is applied for, e.g., a number of selected wavelength6 suited to this disease, within the range of 1000 to 2500 nm, and an uncertainty zone 15 (Fig. 7) iB plotted as ha8 been done hereinafter, but based upon the wavelengths suited to this particular disease.
Referring now to Fig. lA ~ lB, an instrument 10 constructed in accord with the invention comprises 20 a catheter 12 to be placed into a patient body, e.g., an artery, a light source portion 20, a detector portion 50, control means 58 and a laser 60.
Catheter 12 has proximal portion 14 comprising a plurality of several, e.g. 7, optical fibers 15, 25 carrying light to a distal end 16 (described hereafter) and returning reflected light to portion 50.
Light source portion 20, Fig. lA, can feature any convenient source of radiation, selected 30 to include significant radiation in the range of from 1000 to 2500 nm. For example, it can comprise a lamp 22, reflector 24, optical focusing elements 26 and a beam splitter 28, BO that the light image reflects off a second beam splitter 30 through a switch 32 to 35 illuminate indivitual fibers 15 of catheter 12, Fig.
lB.
Switch 32 i8 an optical switch, which conventionally provides an intermediate fiber optic , 2~3~3~
34 that i8 anchored at one end 36, with an opposite end 38 that i8 magnetically moved rapidly to the various positions, shown in phantom, that align with ends 140f fibers 15. Such a switch iB available -5 from York.
Detector portion 50 comprises a lens 52, n optical fibers 55 carrying n bifurcated beams 1 2 . 3 from lens 52, and a spectrophotometer 56. Inside the spectrophotometer is a set of n ters Fl, F2 Fn and a corresponding set of n photodetectors 54, for scanning each of the optical fibers of catheter 12 at the wavelengths selected by filters Fl, F2. . . Fn. Suitable photodetectors include germanium, lead sulfide, lead selenide or indium galium arsenide detectors. The value of n for the detectors, filters, and fibers 55 is dependent on the number of wavelengths needed, as discussed hereinafter. If n > > 19, then the filters preferably are replaced with a dispersive device such as a grating or prism, as in a monochromator or spectrograph.
Any spectrophotometer 56 is useful for this purpose. The output of spectrophotometer 56 is analyzed by control means 58, that includes computing means of any suitable type to do the numeric analysis described below and to solve an eguation, notet hereinafter. Control means 58 in turn provides a control signal to laser 60, to fire a laser beam along any one of the optic fibers 15 that is 30 determined to be viewing a diseased site, but only .
along such fibers. Switching mechanism 32 is used to switch the laser to an appropriate fiber, which can be the same switching mechanism as described for illuminating each of the optic fibers 15 with light from source 22.
As shown in Fig.2, distal end 16 comprises a transparent shield 62 adjacent the focusing ends 64 ~ ~ 3 ~
of fiber optics 15. Such ends deliver a cone of light, 70, Fig. 3, that is divided into separate cones 72a, 72b,...up to 72m, or m cones for m fibers. Preferably, m = 7. Laser light for treatment also is confined to each cone 72a, etc. but the depth of treatment can be, and preferably is, less deep, as shown by the shaded portion. Thus, for the NIR range of 1000 to 2500 nm, penetration depth for examination is from about l mm to about 5 mm, whereas treatment depth is preferably from about 5 ~m to about lO0 ~m. However, treatment depth can be linearly scaled as degcribed hereafter.
The same cones of emitted light 72a...72m represent the tissue that reflects back the emitted light, except to the extent it is absorbed.
Preferably control means 58 u~es a disease index equation regressed to fit large numbers of patient data 80 as to be predictive from the absorbance, or the first or second derivative of absorbance, at the minimum number of wavelengths within the range of 1000 to 2500 nm, needed to discriminate tissue. That is, a spectrophotometer 56 can read absorbance at wavelength data points adjacent to each of the preferred wavelengths, to allow a first and/or a second derivative to be calculated and compared against a threshold value.
Thus, a useful di~ease equation index, i~ preferably of the form Y + Cl A('Al) + C2 A(~2) + cn A(~n) where A(~i) is the absorbance, or the first or second derivative of the absorbance, depending upon the confidence levels of the raw data - that i8, how likely is it that a particular spot illuminated by the catheter i8 totally healthy, or totally diseased. The value of n is determined as the minimum number needed to assure accurate and reliable ,, ., ~,. ;..-. ,. . , - ., . ., . . . -., , . , ~, .~ ".. , ..~- .. .....
. . i , . . - . .
2 ~
prediction. This in part depends upon the aperture of the illuminating beam and thus the area of the tissue examined. The larger the area, the less likely it is that the tissue is tot~Lly healthy or - 5 unhealthy. Thus, if the diameter of the area viewed is no larger than about 100 ~m, it is believed that it iB li~ely that A(~i) can be just the raw absorbance, instead of a derivative, if there i8 no baseline shift.
Referring again to Equation (1), this equation has been derived as follows:
The absorbance of a large number of healthy and diseased tissues is plotted against a continueum of wavelengths between the values of 1000 and 2500 nm. The example charted in Fig. 4 shows only four such curves, where 80 and 82 are healthy tissue of a blood vessel, and 90 and 92 are from diseased tissue characterized as plaque. Because each sample can have a baseline shift that is extraneous to the characteri~tic absorbance, the first and second derivative is preferably taken for all the data.
Fig. S illustrates an example of the second derivative ta~en from the absorbances of aorta from only two different human patients. Curve 100 is a disease curve (representing plaque), and curve 102 s8 a healthy curve. It will be readily apparent that the region between cross-over points is particularly useful, but only where the curves are witely divergent. From the graph of Fig. 5 it is apparent that thig defines the region of from about 1660 nm to about 1690 nm, and then from about 1700 nm to about 1740 nm, or more broadly, from about 1690 nm to about 1740 nm. Even the region of 1690-1700 is useful, unless it turns out to be the cross-over point for ~11 the data being considered, which is not the case for plaque in human aorta.
Next, numerical analysis is done via the standard technique of ~principle component analysis~
. . - . . .
1~ . ,. ; ,; -... . ' i ~ .. , ~ .
1 . . . ' ' ''~. ~ '' ~' . ' '~ ` ' ' '' ' . I .
.: ~ ': :: ' ' .
2 ~ ~ ^3~ ~
(PCA) as described, for example, in "The ~se of Principal Components in the Analysis of Near-Infrared Spectra", Cowe et al, Analytical Chemistry, Vol. 39 (1985), pp. 257-266.) Such a process involves plotting values of the absorbance, or the first or second derivatives of the absorbance measured at, or calculated for, for example, two wavelengths, in at least two and up to n dimensional space, using ~nown PCA mathematics to determine the representative axes of greatest variance in the values (hereinafter, data points). As a result, principle components axis T
is the axis of the greatest variation in the data, regardless of the cause of that variation. Axis T2 is chosen, ~ig. 6, to represent the next greatest axis of variation, and typically represents some variance factor other than that plotted on Tl.
The purpose of the exercise is to determine a) what wavelengths, if any, correlate to a maximum digtinction between tissue samples, and b) whether such distinctions correlate to disease conditions.
In Fig. 5, one can see that a plausible set of Lambda~s would be, e.g. 1678 nm and 1714 nm.
However, because many samples and many curves are reguired to pic~ the best wavelengths, the human eye cannot readily identify the best wavelengthY.
Instead, when the Tl scores from the PCA analysis are obtained, a new plot, Fig. 7, is prepared.
Multiple linear regression on all the sample spectra, using the Tl scores as input data and using a 95%
confidence limit, provides a fit to the data. The predicted values are shown on the y-axis. For plaque in human aorta, n f ~n need only be equal to 2.
Using this data, the equation is solved to determine the coefficients, and the equation then for line 200 ig found to be:
(2) y = -158.77 - 3.72 x 106 A(~l) +
2.03x106 A(~2), for ~1 = 1714 nm and ~2 = 1678 nm.
' ' ~ ,', ~, - 2~3~
Next, all the samples used in analysis are examined by a skilled pathologist, to determine which samples are healthy and which are diseased. For plaque in a blood veæsel, containing cholesterol esters and calcification as the primary distinguishing components, we have found that the graph of Fig. 7 i6 in fact a plot discriminating diseased from healthy tisgue. Stated in other words, the principle component axis Tl has been found to be digtinguishing the samples based upon whether or not they are diseaged, as the primary distinguishing feature.
From this discovery, we have ascertained a threshold value of y which is a predictive of diseaged conditions. That value in Fig. 7 has been found to be any value of y less than -8Ø Thus, the instrument of this invention determines that plaque is present if and when the instrument determines that y < -8.0, using only the second derivatives of two wavelengths being read, for example, 1714 and 1678 nm. Both equation (2) and the threshold value of -~.0 are stored in control means 58.
It will be seen that there is a range, marked U for "uncertainty", Fig. 7, of values "y"
that is not predictive either way. Such values occur due in pa~t to the ability of the near infrared to penetrate through to healthy underlying tissues, Fig. 8, unlike W or visible diagnostic radiation used in the prior art. The actual boundaries for zone U were determined aæ follows: turing the examination of the tissue samples, it was determined that the bunch of "healthyl' samples that i8 closest to the closest diseased samples (Y) was bunch X.
These two bunches were bisected, which produces a Y
value of about -4.5. The highest boundary for zone U
was picked as that value just above healthy bunch X, namely a ~ value of about -1.0, and the same value of , . : . . .: ,.
- . , , .. :. .. . ; ; : : ,,, ;
203~3~
that increment (3.5) was then subtracted from the bisecting value of -4.5 to produce the other bountary -8Ø
Regarding the values on the y-axis of Fig.
7, the relative scale results from the difficulty in defining and quantifying what is a ~diseased state"
of the tissue. If a clear and descriptive definition of disease could be agreed upon, and if a method could be found for extracting the diseage components and quantifying them (percent weight or other form of chemical concentration), then the y-scale could be made absolute. The method proposed for using near IR
wavelengths for tissue discrimination described herein would remain the same, except that one would use the absolute y-scale. In absence of such definitions and data, however, the use of expert pathology and principle component analysis has allowed for a relative scale which can function to provide the advantages noted herein.
Regarding the treatment that is applied to the identified diseased tissue, a variety of treatments are possible and conventional. Any such treatment ~nown to be done via a catheter is useful with this invention. Preferred is surgical removal of the tissue, and most preferred i~ laser ablation.
Optionally, auxilliary features can also be included on the catheter (not shown). For example, the catheter can include expandable balloons either for positioning or treatment.
Regarding laser ablation, a wide variety of lasers 60 can be coupled to the optics of the laser to perform such ablation. Such lasers are well-known and detailed descriptions are not needed. The selection will depend partly on the desired result.
For example, pul~ed 308 nm xenon chloride excimer lasers can be used, and have been described, for example, in "Laser Ablation of ~uman Atherosclerotic : ~ :
2 ~ 3 ~
Plaque," J~ L-~oll. Ca~iol~, Vol. 5, pp. 929-933 (1985). Such a laser can be operated to remove 17 ~m of tissue per pulse.
Other useful lasers include any other~ that - 5 are heavily attenuated by tissues, such as Er:~AG or ~olmium:~AG.
The method of the invention will be readily apparent from the preceding. In brief, catheter 16, Fig. 1, is inserted into the patient's body at a 10 guitable site, and fed along the cardiovascular system to a suspected site. At the suspected site, the light ~ource of portion 20 is cycled through each of the optic fibers 15 to illuminate that spot, Fig.
3. Simultaneously, reflected light passes out each 15 of fibers 15 when each fiber is switched ~equentially to detectors 54, Fig. 1. Each of these fibers 15 will deliver a spectrum of absorption controlled by ers Fl, F2 Fn~ within the range of 1000 to 2500 nm, as shown in Fig. 9. Some of these 20 will reflect light from the blood itself (group 15'), some from healthy tissue (group 15"), and some from tiseased, or plague tissue (group 15 " '). Control means 58, Fig. 1, then specifically examines the absorption at the selected wavelengths, e.g., ~1 and ~2~ which for Fig. 7 are 1678 and 1714. From this the second derivative is calculated for ~1 and ~2. The value of y in equation (1) is then calculated, and in the case of plaque and chole6terol esters, if that value i8 less than -8.0, for a given 30 fiber 15, then laser 60 is fired either automatically or by manual operation to ablate ~way the disea~ed tissue.
As noted above, it is unli~ely that the plot of Fig. 5 represents any true cross-over point, since only two curves are shown, out of the 42 samples actually used to produce Figs. 6 and 7. ~owever, in the event cross-over point 1740 nm were found to be - . , ~.: ,., : ~ :
.. i . . ..
~ $ ~
stable and valid for all 42 curves, that point can be used to calibrate the instrument.
~ ncertainty region ~ of Fig. 7 has usefulness in the practice of the invention, ~ince S the instrument must be able to detect conditions where plaque has consumed most of the wall of the blood vessel. In the condition shown in Fig. 8, blood vessel 210 i8 defined by endothelial layer 212 between which blood flows, arrow 213, with plaque 10 deposits such as deposit 214 existing on layer 212.
Under layer 212 is intima layer 216, and below that, media layer 218. In this esample, plaque has built up to almost completely fill layer 218, at region 220. Below layer 218 is the atventitia layer 222, 15 and below that, fat 224.
The instrument of thig invention i8 able to detect the adventitia layer 222 underneath the plaque, and deliver a signal that is part healthy and part diseased, thus falling within region "U" of Fig.
20 7. This will force the instrument to timely cease laser ablation, even though plague remains as the form of the media at region Q. In contrast, UV/visible diagnostic instruments will not detect the adventitia layer 222 underneath the plaque, and will 25 ~eep firing until all the plaque i8 gone.
Unfortunately the last ablation step ("burn~ ff4) will be li~ely to ablate too far through the adventitia, thu6 perforating the vessel. In contrast, however, after "burn" #3, or even after "burn" ff2 i8 done with 30 this invention, the diagnostic phase of ~hi~
invention will detect enough of the healthy tissue of layer 222 underneath, as to place the "y" values of equation ~1 in the "uncertainty" region ~, and no more laser treatment will be done, thus avoiding 35 perforation of the blood vessel. (The use of the term "burn" in Fig. 8 i~ a short-hand reference to the ablation that occurs. Strictly spea~ing, no ' " ' ' ;.... ' '' ~ ., "'. :...... . '',' ' ' ' '' :,: ,` .
. . . . . . ~ :
~Q~3 ~
burning of the tissue is desired or occurs, but rather ablation.) Still further, the dosage value of the laser esposure, that is, both the power and the length of -5 the ablation, is preferably adjusted depending upon how far away the value of "y" i8, Fig. 7, compared to the threshold (-8.0 in the above example.) Ma~imum dosage is assigned to - 40, and it can be scaled back linearly to zero at -8Ø
Fig. 10 is a further illustration of a use of the invention. This plot shows curves 300 and ;i 302, of which 300 is diseased. The guestion iR, curve 302. The importance of this curve is that, visually, the aorta involved had the ~~nC~ of being diseased. ~owever, it turned out this was superficial only, due to a thin layer of lipids.
~nderneath, this aorta was perfectly healthy, as was ~gnfiL~d by the application of eguation (1), e~amination of curve 302 and the plot of Fig. 7, where y was about 12. The reason of course was the ability of the NIR to penetrate the lipid layer (of only about 50-100 nm) to determine that, underneath, the tissue was very healthy. This detection would NOT have been possible using only UV/visible illumination and detection.
Exam~
The following examples are illustrative only of the procedure used to practice this invention.
The condition of all of the data of the plot of healthy versus diseased samples that comprise Figs. 6 and 7 was determined by a pathological review of samples as follows:
Exa~ l: Four Samples From Patient ~1 Four aorta samples, one square inch in size 3S each, were submitted in 10% buffered formalin for microscopic evaluation. A gross pathologic report with age, cause of death, and description of lesions was not available.
-.. - - - . .
.. .' ~' ' ,: : . . -, .
.
203~3~.
The samples were labeled as lA, lB, lC and lD. The above ~pecimens were ~ept in buffered formalin for ~even days before trimming. Samples of each ~pecimen were trimmed to reveal a cro~ ~ection 5 of the arterial wall. Tissue sampleo were processed by routine histologic techniques and e~amined microscopically.
The samples were described in the increasing order of severity of lesions. All samples contained 10 a variable number of bacterial colonies, but their number and location were not recorded because their growth probably occurred after death.
lA. In~ima: The intima comprised only appro~imately 1/6 of the aorta wall. The majority of 15 the cross section contained hyalinized collagenous fibers, extracellular matri~, and few myointimal cells separated by minor edema.
~ ia: This layer comprised appro~imately 4/6 of the aorta wall. It contained 20 amorphous ~rount sub~tance (probably proteoglycans), concentrically arranged laminae of elastic tis8ue, and intervening smooth muscles.
Adventi~ia: Thi~ layer comprised approximately 116 of the aorta wall. It consisted of a large number of adipose tissue cells, some elastic fibers, and a few thin-wallet nutrient vessels (vasa vasorum).
lC. Intima: The thic~ness of the intima increased to appro~imately 2/6 of the aorta wall.
30 The extracellular matrix and hyalinized collagenous fibers accounted for all of increase in the thic~ness of this layer. The number of myointimal cell8 Wa8 unchanged when compared to lA gample.
M~ia: The thic~ness of this layer comprised about 3l6 of the aorta wall.
Microscopically it was similar to the corresponding layer of lA. In adtition, there were few sm~ll ~s~35~3~
accumulations of red blood cells ~eparating elastic fibers.
Ad~enti~ia: The thic~ness of this layer comprised appro~imately l/6 of the aorta wall.
S The microscopic appearance was similar to the corresponding layer of lA. i~
lD. In~ima: This layer comprised about 3/6 of the aorta wall. One complete and one incomplete atheromatous plaque were present on the section. On lO the luminal 8ide the plaques were covered by a fibrous cap consisting of dense layers of hyalinized collagenous fibers, fibrin-li~e strands, and amorphous eosinophilic material. The center of the plaque contained crystals of cholesterol esters, fibrin-li~e structures, ant granular ant amorphous eosinophilic material.
~edia: The media comprised about 2/6 of the aorta wall. Microscopically, it was similar to the corresponding layer of lA.
lB. Intima: The thic~ness of this layer comprised about 3/6 of the aorta wall. It contained a single ulcerated atheromatous plague. The remnants of the fibrous cap were folded bac~ over the adjacent endothelium. The crater~ e center of the plaque, comprised of crystals of cholesterol esters and granular and amorphous eosinophilic substance, became part of the aortal lumen. In addition, few macrophage~ e cells, hemosiderin-li~e pigment, and two ~mall groups of red blood cells were present in 30 the plaque. Intima that was adjacent to the plaque consisted of hyalinized collagen fibers, a few atrophic muscle fibers, fibrin-li~e structures, and amorphous eosinophilic material.
Media and Int~m~: The media and intima comprised approximately 2/6 and 116 of the aorta wall re~pectively. Microscopically, they were similar to the corresponding structures of the lA.
,~
2~6~
The conclusion was, sample lA was healthy albeit with fatty deposits, lB was diseased, lC was healthy, and lD was diseased.
Multiple specimens, five from patient ~2 identified as A, B, C, D and E and three from patient 3# itentified as A, B and C, on ~guare inch in size each, were submitted in 10% buffered formalin for microscopic evaluation.
Information on age, cause of death ant r description of lesion~ was not submitted with the specimens.
The above specimens were ~ept in buffered formalin for seven days before trimming. Each specimen was trimmed to reveal on cross section of the arterial wall. Tissue specimens were processed by routine histologic technigues and esamined microscopically.
All specimens contained a variable number of bacterial colonies, but their number and location were not recorded because their growth probably occurred after death.
~ecimen~ 2A and_~
In~ima: The intima comprised approximately 2/6 of the aorta wall. The ~ajority of the cross section contained hyalinized collagenous fibers, extracellular matris, and a few myointimal and mononuclear cells. Dystrophic calcification was spread throughout the intima and ranged in size from small foci to a large plaque involving the entire thickness of the intima. Each plague was covered by thick fibrous cap.
Media: This layer comprised approximately 3/6 of the aorta wall. It contained amorphous ground substance, concentrically arranged laminae of elastic tissue, intervening smooth muscles, and a few scattered macrophage~.
. . . . . : : . .
,, , ~ . , ;, . , ~, ~ .
~O~fi~ ~
A~k~Dtiti~: This layer comprised approximately 116 of the aorta wall. It contained irregularly arranged collagen and elastic fibers, and a few nutrient vessels.
The fibrous cap over the calcified plaque in specimen 2E was torn during the processing.
~L~ .
In~ima: The intima compri~ed approximately 2/6 of the aorta wall. The majority of the cross ~ection contained hyalinized collagenous fibers, extracellular matri~, and a view myointimal cells.
Media: This layer comprised approximately 3/6 of the aorta wall. it contained amorphous ground substance, concentrically arranged laminae of elastic tissue, intervening smooth muscles, and a few scattered macrophages.
AdventiSia: This layer compriset appro~imately l/6 of the aorta wall. It contained irregularly arranged collagen and elastic fibers, and a few nutrient vessels.
S~ecim~D~ 3A. B an~ C
In~ima: This layer was comprised entirely of the endothelium.
~id: The media comprlsed 2/6 to 4/6 of the aorta wall. It contained amorphous ground substance, concentrica}ly arranged laminae of elastic tissue, intervening smooth muscles, and a few scattered macrophages.
Adventi~La: The thic~ness of this layer grew progressively from A to B to C. This layer comprised.from 2/6 to 4/6 of the aorta wall.
It consisted of large numbers of irregularly arranged collagen fibers, elastic fibers, adipose tissue cells, chronic inflammatory cells, and few nutrient vessels. The majority of increase in the thic~ness was attributable to an increase in the number of 2~36~3~
collagen fibers. In the B sample, there was a single accumulation of about 100 lymphoblastoit cells wedged between the collagen fibers.
~ence, the conclusions were as follows:
2A - diseased 2B - healthy 2C - healthy 2D - healthy 2E - diseased 3A - healthy 3B - healthy 3C - healthy Re~re9s iQn All of the samples of Examples 1-3 were then correlated ~n the plots of Figs. 6 and 7, along with gome additional samples to total 42 in all, to e~tablish that the distinguishing factor is in fact the extent of disease present. The resulting equation of y = -158.77 - 3.72 s 106 A(~
2.03 x 106 A(~2) was obtained, where A(~l) i8 the second derivative of the NIR
absorbance at 1714 nm, and A(~2) i8 the ~econd derivative of the NIR absorbance at 1678 nm.
Although only two wavelengths have been ~hown to be sufficient to distinguish plaque from healthy aorts tissue, such a minimum may not apply to other diseased states. That i8, plaque can be characterized by a few chemical components, primarily cholesterol esters and calcification. If another diseased state iB controlled by, say five components, or more details are desired, many more than two wavelengths may be neces~ary.
The invention has been described in detail with particular reference to certain preferred embodiments thereof, but it will be understood that variations and modifications can be effected within the spirit and scope of the invention.
:; . . ~ ................. . - ~ ...... . .
" ' ' ' ' ' ' ' ' : . ' ' " ' ' ' ' ' ',.' .' ' . . ~ ' ' ' : ' '. ! . ~,.,
As noted above, it is unli~ely that the plot of Fig. 5 represents any true cross-over point, since only two curves are shown, out of the 42 samples actually used to produce Figs. 6 and 7. ~owever, in the event cross-over point 1740 nm were found to be - . , ~.: ,., : ~ :
.. i . . ..
~ $ ~
stable and valid for all 42 curves, that point can be used to calibrate the instrument.
~ ncertainty region ~ of Fig. 7 has usefulness in the practice of the invention, ~ince S the instrument must be able to detect conditions where plaque has consumed most of the wall of the blood vessel. In the condition shown in Fig. 8, blood vessel 210 i8 defined by endothelial layer 212 between which blood flows, arrow 213, with plaque 10 deposits such as deposit 214 existing on layer 212.
Under layer 212 is intima layer 216, and below that, media layer 218. In this esample, plaque has built up to almost completely fill layer 218, at region 220. Below layer 218 is the atventitia layer 222, 15 and below that, fat 224.
The instrument of thig invention i8 able to detect the adventitia layer 222 underneath the plaque, and deliver a signal that is part healthy and part diseased, thus falling within region "U" of Fig.
20 7. This will force the instrument to timely cease laser ablation, even though plague remains as the form of the media at region Q. In contrast, UV/visible diagnostic instruments will not detect the adventitia layer 222 underneath the plaque, and will 25 ~eep firing until all the plaque i8 gone.
Unfortunately the last ablation step ("burn~ ff4) will be li~ely to ablate too far through the adventitia, thu6 perforating the vessel. In contrast, however, after "burn" #3, or even after "burn" ff2 i8 done with 30 this invention, the diagnostic phase of ~hi~
invention will detect enough of the healthy tissue of layer 222 underneath, as to place the "y" values of equation ~1 in the "uncertainty" region ~, and no more laser treatment will be done, thus avoiding 35 perforation of the blood vessel. (The use of the term "burn" in Fig. 8 i~ a short-hand reference to the ablation that occurs. Strictly spea~ing, no ' " ' ' ;.... ' '' ~ ., "'. :...... . '',' ' ' ' '' :,: ,` .
. . . . . . ~ :
~Q~3 ~
burning of the tissue is desired or occurs, but rather ablation.) Still further, the dosage value of the laser esposure, that is, both the power and the length of -5 the ablation, is preferably adjusted depending upon how far away the value of "y" i8, Fig. 7, compared to the threshold (-8.0 in the above example.) Ma~imum dosage is assigned to - 40, and it can be scaled back linearly to zero at -8Ø
Fig. 10 is a further illustration of a use of the invention. This plot shows curves 300 and ;i 302, of which 300 is diseased. The guestion iR, curve 302. The importance of this curve is that, visually, the aorta involved had the ~~nC~ of being diseased. ~owever, it turned out this was superficial only, due to a thin layer of lipids.
~nderneath, this aorta was perfectly healthy, as was ~gnfiL~d by the application of eguation (1), e~amination of curve 302 and the plot of Fig. 7, where y was about 12. The reason of course was the ability of the NIR to penetrate the lipid layer (of only about 50-100 nm) to determine that, underneath, the tissue was very healthy. This detection would NOT have been possible using only UV/visible illumination and detection.
Exam~
The following examples are illustrative only of the procedure used to practice this invention.
The condition of all of the data of the plot of healthy versus diseased samples that comprise Figs. 6 and 7 was determined by a pathological review of samples as follows:
Exa~ l: Four Samples From Patient ~1 Four aorta samples, one square inch in size 3S each, were submitted in 10% buffered formalin for microscopic evaluation. A gross pathologic report with age, cause of death, and description of lesions was not available.
-.. - - - . .
.. .' ~' ' ,: : . . -, .
.
203~3~.
The samples were labeled as lA, lB, lC and lD. The above ~pecimens were ~ept in buffered formalin for ~even days before trimming. Samples of each ~pecimen were trimmed to reveal a cro~ ~ection 5 of the arterial wall. Tissue sampleo were processed by routine histologic techniques and e~amined microscopically.
The samples were described in the increasing order of severity of lesions. All samples contained 10 a variable number of bacterial colonies, but their number and location were not recorded because their growth probably occurred after death.
lA. In~ima: The intima comprised only appro~imately 1/6 of the aorta wall. The majority of 15 the cross section contained hyalinized collagenous fibers, extracellular matri~, and few myointimal cells separated by minor edema.
~ ia: This layer comprised appro~imately 4/6 of the aorta wall. It contained 20 amorphous ~rount sub~tance (probably proteoglycans), concentrically arranged laminae of elastic tis8ue, and intervening smooth muscles.
Adventi~ia: Thi~ layer comprised approximately 116 of the aorta wall. It consisted of a large number of adipose tissue cells, some elastic fibers, and a few thin-wallet nutrient vessels (vasa vasorum).
lC. Intima: The thic~ness of the intima increased to appro~imately 2/6 of the aorta wall.
30 The extracellular matrix and hyalinized collagenous fibers accounted for all of increase in the thic~ness of this layer. The number of myointimal cell8 Wa8 unchanged when compared to lA gample.
M~ia: The thic~ness of this layer comprised about 3l6 of the aorta wall.
Microscopically it was similar to the corresponding layer of lA. In adtition, there were few sm~ll ~s~35~3~
accumulations of red blood cells ~eparating elastic fibers.
Ad~enti~ia: The thic~ness of this layer comprised appro~imately l/6 of the aorta wall.
S The microscopic appearance was similar to the corresponding layer of lA. i~
lD. In~ima: This layer comprised about 3/6 of the aorta wall. One complete and one incomplete atheromatous plaque were present on the section. On lO the luminal 8ide the plaques were covered by a fibrous cap consisting of dense layers of hyalinized collagenous fibers, fibrin-li~e strands, and amorphous eosinophilic material. The center of the plaque contained crystals of cholesterol esters, fibrin-li~e structures, ant granular ant amorphous eosinophilic material.
~edia: The media comprised about 2/6 of the aorta wall. Microscopically, it was similar to the corresponding layer of lA.
lB. Intima: The thic~ness of this layer comprised about 3/6 of the aorta wall. It contained a single ulcerated atheromatous plague. The remnants of the fibrous cap were folded bac~ over the adjacent endothelium. The crater~ e center of the plaque, comprised of crystals of cholesterol esters and granular and amorphous eosinophilic substance, became part of the aortal lumen. In addition, few macrophage~ e cells, hemosiderin-li~e pigment, and two ~mall groups of red blood cells were present in 30 the plaque. Intima that was adjacent to the plaque consisted of hyalinized collagen fibers, a few atrophic muscle fibers, fibrin-li~e structures, and amorphous eosinophilic material.
Media and Int~m~: The media and intima comprised approximately 2/6 and 116 of the aorta wall re~pectively. Microscopically, they were similar to the corresponding structures of the lA.
,~
2~6~
The conclusion was, sample lA was healthy albeit with fatty deposits, lB was diseased, lC was healthy, and lD was diseased.
Multiple specimens, five from patient ~2 identified as A, B, C, D and E and three from patient 3# itentified as A, B and C, on ~guare inch in size each, were submitted in 10% buffered formalin for microscopic evaluation.
Information on age, cause of death ant r description of lesion~ was not submitted with the specimens.
The above specimens were ~ept in buffered formalin for seven days before trimming. Each specimen was trimmed to reveal on cross section of the arterial wall. Tissue specimens were processed by routine histologic technigues and esamined microscopically.
All specimens contained a variable number of bacterial colonies, but their number and location were not recorded because their growth probably occurred after death.
~ecimen~ 2A and_~
In~ima: The intima comprised approximately 2/6 of the aorta wall. The ~ajority of the cross section contained hyalinized collagenous fibers, extracellular matris, and a few myointimal and mononuclear cells. Dystrophic calcification was spread throughout the intima and ranged in size from small foci to a large plaque involving the entire thickness of the intima. Each plague was covered by thick fibrous cap.
Media: This layer comprised approximately 3/6 of the aorta wall. It contained amorphous ground substance, concentrically arranged laminae of elastic tissue, intervening smooth muscles, and a few scattered macrophage~.
. . . . . : : . .
,, , ~ . , ;, . , ~, ~ .
~O~fi~ ~
A~k~Dtiti~: This layer comprised approximately 116 of the aorta wall. It contained irregularly arranged collagen and elastic fibers, and a few nutrient vessels.
The fibrous cap over the calcified plaque in specimen 2E was torn during the processing.
~L~ .
In~ima: The intima compri~ed approximately 2/6 of the aorta wall. The majority of the cross ~ection contained hyalinized collagenous fibers, extracellular matri~, and a view myointimal cells.
Media: This layer comprised approximately 3/6 of the aorta wall. it contained amorphous ground substance, concentrically arranged laminae of elastic tissue, intervening smooth muscles, and a few scattered macrophages.
AdventiSia: This layer compriset appro~imately l/6 of the aorta wall. It contained irregularly arranged collagen and elastic fibers, and a few nutrient vessels.
S~ecim~D~ 3A. B an~ C
In~ima: This layer was comprised entirely of the endothelium.
~id: The media comprlsed 2/6 to 4/6 of the aorta wall. It contained amorphous ground substance, concentrica}ly arranged laminae of elastic tissue, intervening smooth muscles, and a few scattered macrophages.
Adventi~La: The thic~ness of this layer grew progressively from A to B to C. This layer comprised.from 2/6 to 4/6 of the aorta wall.
It consisted of large numbers of irregularly arranged collagen fibers, elastic fibers, adipose tissue cells, chronic inflammatory cells, and few nutrient vessels. The majority of increase in the thic~ness was attributable to an increase in the number of 2~36~3~
collagen fibers. In the B sample, there was a single accumulation of about 100 lymphoblastoit cells wedged between the collagen fibers.
~ence, the conclusions were as follows:
2A - diseased 2B - healthy 2C - healthy 2D - healthy 2E - diseased 3A - healthy 3B - healthy 3C - healthy Re~re9s iQn All of the samples of Examples 1-3 were then correlated ~n the plots of Figs. 6 and 7, along with gome additional samples to total 42 in all, to e~tablish that the distinguishing factor is in fact the extent of disease present. The resulting equation of y = -158.77 - 3.72 s 106 A(~
2.03 x 106 A(~2) was obtained, where A(~l) i8 the second derivative of the NIR
absorbance at 1714 nm, and A(~2) i8 the ~econd derivative of the NIR absorbance at 1678 nm.
Although only two wavelengths have been ~hown to be sufficient to distinguish plaque from healthy aorts tissue, such a minimum may not apply to other diseased states. That i8, plaque can be characterized by a few chemical components, primarily cholesterol esters and calcification. If another diseased state iB controlled by, say five components, or more details are desired, many more than two wavelengths may be neces~ary.
The invention has been described in detail with particular reference to certain preferred embodiments thereof, but it will be understood that variations and modifications can be effected within the spirit and scope of the invention.
:; . . ~ ................. . - ~ ...... . .
" ' ' ' ' ' ' ' ' : . ' ' " ' ' ' ' ' ',.' .' ' . . ~ ' ' ' : ' '. ! . ~,.,
Claims (21)
1. An instrument for detecting and treating selectively, diseased portions of body tissue, said instrument comprising a) means for illuminating portions of said body tissue with light energy of predetermined wavelengths selected from the range of between about 1000 and 2500 nm, said predetermined wavelengths being effective to be selectively absorbed by a preselected component of said tissue, b) means for collecting the light at said predetermined wavelengths that is not absorbed by said tissue portions, c) means for examining the amounts of absorbance of said light by said illuminated body tissue as determined from said collected light, and d) discriminating means for discriminating one illuminated tissue component from another illuminated tissue component at said wavelengths, whereby certain illuminated portions of the body tissue are identified and located as being diseased.
2. An instrument as defined in claim 1, and further including e) means for treating only the identified and located tissue portions.
3. An instrument as defined in claim 1, wherein said illuminating means include light-energy generating means for generating said predetermined wavelengths, and at least one optical fiber for transmitting said wavelengths.
4. An instrument as defined in claim 1, wherein said illuminating means selectively illuminate at a plurality of wavelengths selectively absorbed by disease components of choice of said tissue, and said discriminating means discriminates diseased tissue from healthy tissue.
5. An instrument as defined in claim 4, wherein said wavelengths are selectively absorbed by cholesterol esters and said body tissues are cardiovascular tissues.
6. An instrument as defined in claim 5, wherein said wavelengths are selected from between about 1660 nm and about 1740 nm.
7. A surgical instrument suitable for atherosclerosis treatment, comprising a catheter having a distal end constructed to penetrate a blood vessel, a proximal end constructed to remain outside the blood vessel, and a body portion connecting said ends, said ends and body portion including at least one optical fiber capable of delivering from one end, illumination light of desired wavelengths, said distal end further including optical means for transmitting and receiving light energy from said fibers to a blood vessel, and from the illuminated blood vessel to said fibers, respectively;
said proximal end further including a) means for generating light energy at predetermined wavelengths between about 1660 nm and about 1740 nm, b) means for delivering said generated energy to said at least one fiber, c) means for detecting the amount of such generated energy that is not absorbed by illuminated tissue in a blood vessel and d) means for discriminating illuminated healthy tissue from illuminated diseased tissue at said wavelengths, said instrument further including treating means for selectively treating only the illuminated diseased tissue as determined by said discriminating means.
said proximal end further including a) means for generating light energy at predetermined wavelengths between about 1660 nm and about 1740 nm, b) means for delivering said generated energy to said at least one fiber, c) means for detecting the amount of such generated energy that is not absorbed by illuminated tissue in a blood vessel and d) means for discriminating illuminated healthy tissue from illuminated diseased tissue at said wavelengths, said instrument further including treating means for selectively treating only the illuminated diseased tissue as determined by said discriminating means.
8. An instrument as defined in claim 3 or 7, wherein said predetermined wavelengths generated by said light-energy generating means comprise wavelengths that are absorbed by at least some of the components of deposits that are not present in healthy blood vessel tissue.
9. An instrument as defined in claim 6 or 7, wherein said predetermined wavelengths are 1678 ?
20 nm and 1714 ? 20 nm.
20 nm and 1714 ? 20 nm.
10. An instrument as defined in claim 3 or 7, wherein said treating means comprise an ablating laser and switching means operatively connecting said ablating laser to said at least one fiber only when said fiber is illuminating diseased tissue as determined by said discriminating means.
11. An instrument as defined in claim 1 or 7, wherein said discriminating means comprise i) means for converting said absorbance amounts into second derivative values, ii) storage means for storing a disease index equation, iii) means for solving this equation using said second derivative values, and iv) comparing means for comparing said disease index value against a threshold value for diseased and healthy conditions of said tissues.
12. An instrument as defined in claims 1 or 7, wherein said discriminating means i) uses the equation y = Co + C1A(.lambda.1) + C2A(.lambda.2) wherein A(.lambda.1) + A(.lambda.2) are the absorbances or the first or second derivatives of the absorbances of said tissue at said two predetermined wavelengths, and Co, C1 and C2 are predetermined constants, and ii) compares the calculated y value against a predetermined threshold value.
13. A method of detecting certain tissue in body tissue, comprising the steps of a) illuminating portions of said body tissue with light energy of predetermined wavelengths selected from the range of between about 1000 and about 2500 nm, said predetermined wavelengths being effective to be selectively absorbed by a preselected component of said tissue, b) collecting the light at said predetermined wavelengths that is not absorbed from said tissue portions, c) examining the amounts of absorbance of said light as determined from the collected amounts not absorbed by said illuminated body tissue, and d) discriminating one illuminated tissue component from another illuminated tissue component at said wavelengths, whereby certain illuminated portions of body tissue are identified and located.
14. A method of treating diseased but not healthy tissue in a body vessel, comprising the steps of i) detecting which portions are diseased and which are healthy by the steps of claim 13, and ii) treating only the diseased portions.
15. A method as defined in claim 13, wherein said step d) comprises the steps of i) converting said absorbance amounts into second derivative values, ii) solving a disease index equation using said second derivative values, and iii) comparing means for comparing said solved disease index value against a threshold value for diseased conditions of said tissues.
16. A method as defined in claim 13, wherein said step a) comprises the steps of illuminating at wavelengths selectively absorbed by preselected disease components of said tissue, and said step d) discriminates diseased tissue from healthy tissue.
17. A method as defined in claim 16, wherein said wavelengths are selectively absorbed by cholesterol esters and said body tissues are cardiovascular tissues.
18. A method as defined in claim 17, wherein said wavelengths are selected from between 1660 nm ant about 1740 nm.
19. A method as defined in claim 13, wherein said step a) comprises iluminating said body tissue at two predetermined wavelengths .lambda.1 and .lambda.2 within said 1000-2500 µm range, and said step d) comprises calculating y from the equation:
y = Co + C1A(.lambda.1) + C2A(.lambda.2) wherein A(.lambda.1) + A(.lambda.2) are the absorbances or the first or second derivatives of the absorbances of said tissue at said two predetermined wavelengths, and Co, C1 and C2 are predetermined constants, ant comparing the calculated y value against a predetermined threshold value.
y = Co + C1A(.lambda.1) + C2A(.lambda.2) wherein A(.lambda.1) + A(.lambda.2) are the absorbances or the first or second derivatives of the absorbances of said tissue at said two predetermined wavelengths, and Co, C1 and C2 are predetermined constants, ant comparing the calculated y value against a predetermined threshold value.
20. A method as defined in claim 19, wherein said equation is y = -158.77 - 3.72 x 106 A(.lambda.1) +
2.03 x 106 A(.lambda.2).
2.03 x 106 A(.lambda.2).
21. A method as defined in claim 14, wherein said treating step ii) comprises exposing the diseased portions to laser light at a dosage that is proportional to the certainty determined by said detecting step i) that said exposed portions are diseased.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US568,452 | 1990-07-16 | ||
US07/568,452 US5197470A (en) | 1990-07-16 | 1990-07-16 | Near infrared diagnostic method and instrument |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2036031A1 true CA2036031A1 (en) | 1992-01-17 |
Family
ID=24271358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002036031A Abandoned CA2036031A1 (en) | 1990-07-16 | 1991-02-08 | Near infrared diagnostic method and instrument |
Country Status (4)
Country | Link |
---|---|
US (1) | US5197470A (en) |
EP (1) | EP0467459A3 (en) |
JP (1) | JP3234249B2 (en) |
CA (1) | CA2036031A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5733507A (en) * | 1995-06-07 | 1998-03-31 | Inphocyte, Inc. | Biological cell sample holder for use in infrared and/or Raman spectroscopy analysis holder |
US5848977A (en) * | 1996-02-16 | 1998-12-15 | Inphocyte, Inc. | Sample holder for cells |
Families Citing this family (226)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5402778A (en) * | 1993-01-19 | 1995-04-04 | Nim Incorporated | Spectrophotometric examination of tissue of small dimension |
US5564417A (en) * | 1991-01-24 | 1996-10-15 | Non-Invasive Technology, Inc. | Pathlength corrected oximeter and the like |
US6708048B1 (en) | 1989-02-06 | 2004-03-16 | Non-Invasive Technology, Inc. | Phase modulation spectrophotometric apparatus |
US5261410A (en) * | 1991-02-07 | 1993-11-16 | Alfano Robert R | Method for determining if a tissue is a malignant tumor tissue, a benign tumor tissue, or a normal or benign tissue using Raman spectroscopy |
US5217453A (en) * | 1991-03-18 | 1993-06-08 | Wilk Peter J | Automated surgical system and apparatus |
US5582185A (en) * | 1991-04-16 | 1996-12-10 | The United States Of America As Represented By The Department Of Health And Human Services | Device for evaluating optical elements by reflected images |
US6485413B1 (en) | 1991-04-29 | 2002-11-26 | The General Hospital Corporation | Methods and apparatus for forward-directed optical scanning instruments |
US6501551B1 (en) | 1991-04-29 | 2002-12-31 | Massachusetts Institute Of Technology | Fiber optic imaging endoscope interferometer with at least one faraday rotator |
US6111645A (en) | 1991-04-29 | 2000-08-29 | Massachusetts Institute Of Technology | Grating based phase control optical delay line |
US6134003A (en) * | 1991-04-29 | 2000-10-17 | Massachusetts Institute Of Technology | Method and apparatus for performing optical measurements using a fiber optic imaging guidewire, catheter or endoscope |
US5320620A (en) * | 1991-07-01 | 1994-06-14 | Laser Centers Of America | Laser surgical device with blunt flat-sided energy-delivery element |
ATE172623T1 (en) * | 1991-12-17 | 1998-11-15 | Dynamics Imaging Inc | METHOD AND DEVICE FOR DIAGNOSING LIVING ORGANISMS |
JPH05228098A (en) * | 1992-02-20 | 1993-09-07 | Asahi Optical Co Ltd | Thermoendoscope |
US5792050A (en) * | 1992-07-06 | 1998-08-11 | Alam; Mary K. | Near-infrared noninvasive spectroscopic determination of pH |
US5699797A (en) * | 1992-10-05 | 1997-12-23 | Dynamics Imaging, Inc. | Method of investigation of microcirculation functional dynamics of physiological liquids in skin and apparatus for its realization |
EP0669820B1 (en) * | 1992-11-18 | 1997-04-16 | Spectrascience, Inc. | Apparatus for diagnostic imaging |
US5383467A (en) * | 1992-11-18 | 1995-01-24 | Spectrascience, Inc. | Guidewire catheter and apparatus for diagnostic imaging |
US6002958A (en) * | 1992-12-24 | 1999-12-14 | Dynamics Imaging, Inc. | Method and apparatus for diagnostics of internal organs |
WO1994028795A1 (en) * | 1992-12-24 | 1994-12-22 | E.G. Vision, Inc. | Method and apparatus for diagnostics of internal organs |
US5987346A (en) * | 1993-02-26 | 1999-11-16 | Benaron; David A. | Device and method for classification of tissue |
US5596992A (en) * | 1993-06-30 | 1997-01-28 | Sandia Corporation | Multivariate classification of infrared spectra of cell and tissue samples |
ZA948393B (en) * | 1993-11-01 | 1995-06-26 | Polartechnics Ltd | Method and apparatus for tissue type recognition |
US5747789A (en) * | 1993-12-01 | 1998-05-05 | Dynamics Imaging, Inc. | Method for investigation of distribution of physiological components in human body tissues and apparatus for its realization |
US5409012A (en) * | 1993-12-30 | 1995-04-25 | Boston Scientific Corporation | Sample collection using catheter with expandable member |
US5599298A (en) * | 1993-12-30 | 1997-02-04 | Boston Scientific Corporation | Bodily sample collection balloon catheter method |
US5459317A (en) * | 1994-02-14 | 1995-10-17 | Ohio University | Method and apparatus for non-invasive detection of physiological chemicals, particularly glucose |
US6192262B1 (en) | 1994-02-23 | 2001-02-20 | Dobi Medical Systems, Llc | Method of living organism multimodal functional mapping |
US5865743A (en) * | 1994-02-23 | 1999-02-02 | Dynamics Imaging, Inc. | Method of living organism multimodal functional mapping |
DE4410888A1 (en) * | 1994-03-29 | 1995-10-05 | Zeiss Carl Jena Gmbh | Apparatus for irradiating human tissue using multi-wavelength IR light |
US5730133A (en) * | 1994-05-20 | 1998-03-24 | Dynamics Imaging, Inc. | Optical functional mamoscope |
US5523054A (en) * | 1995-01-31 | 1996-06-04 | Johnson & Johnson Clinical Diagnostics, Inc. | Test element for quantitative NIR spectroscopic analysis |
US5660181A (en) * | 1994-12-12 | 1997-08-26 | Physical Optics Corporation | Hybrid neural network and multiple fiber probe for in-depth 3-D mapping |
US6618614B1 (en) | 1995-01-03 | 2003-09-09 | Non-Invasive Technology, Inc. | Optical examination device, system and method |
US5589932A (en) * | 1995-02-08 | 1996-12-31 | University Of South Florida | Spectrophotometric method and apparatus for the characterization of blood and blood types |
US6615071B1 (en) | 1995-09-20 | 2003-09-02 | Board Of Regents, The University Of Texas System | Method and apparatus for detecting vulnerable atherosclerotic plaque |
ATE221338T1 (en) | 1995-09-20 | 2002-08-15 | Texas Heart Inst | YINDICATION OF THERMAL DISCONTINUITY ON VESSEL WALLS |
US6763261B2 (en) | 1995-09-20 | 2004-07-13 | Board Of Regents, The University Of Texas System | Method and apparatus for detecting vulnerable atherosclerotic plaque |
US6031232A (en) * | 1995-11-13 | 2000-02-29 | Bio-Rad Laboratories, Inc. | Method for the detection of malignant and premalignant stages of cervical cancer |
US6146897A (en) * | 1995-11-13 | 2000-11-14 | Bio-Rad Laboratories | Method for the detection of cellular abnormalities using Fourier transform infrared spectroscopy |
US6022309A (en) * | 1996-04-24 | 2000-02-08 | The Regents Of The University Of California | Opto-acoustic thrombolysis |
US20020045890A1 (en) * | 1996-04-24 | 2002-04-18 | The Regents Of The University O F California | Opto-acoustic thrombolysis |
US5879294A (en) * | 1996-06-28 | 1999-03-09 | Hutchinson Technology Inc. | Tissue chromophore measurement system |
US6296608B1 (en) * | 1996-07-08 | 2001-10-02 | Boston Scientific Corporation | Diagnosing and performing interventional procedures on tissue in vivo |
US20020077564A1 (en) * | 1996-07-29 | 2002-06-20 | Farallon Medsystems, Inc. | Thermography catheter |
US5775806A (en) * | 1996-09-12 | 1998-07-07 | The United States Of America As Represented By The Secretary Of The Air Force | Infrared assessment system |
US7603166B2 (en) | 1996-09-20 | 2009-10-13 | Board Of Regents University Of Texas System | Method and apparatus for detection of vulnerable atherosclerotic plaque |
US5906636A (en) | 1996-09-20 | 1999-05-25 | Texas Heart Institute | Heat treatment of inflamed tissue |
WO1998022184A1 (en) * | 1996-11-21 | 1998-05-28 | Boston Scientific Corporation | Mucosal ablation using light |
US6119031A (en) | 1996-11-21 | 2000-09-12 | Boston Scientific Corporation | Miniature spectrometer |
US20060149343A1 (en) * | 1996-12-02 | 2006-07-06 | Palomar Medical Technologies, Inc. | Cooling system for a photocosmetic device |
US5830146A (en) * | 1997-03-17 | 1998-11-03 | Polartechnics Limited | Sheathed probes for tissue type recognition |
GB9707414D0 (en) * | 1997-04-11 | 1997-05-28 | Imperial College | Anatomical probe |
US5984861A (en) * | 1997-09-29 | 1999-11-16 | Boston Scientific Corporation | Endofluorescence imaging module for an endoscope |
US6096065A (en) * | 1997-09-29 | 2000-08-01 | Boston Scientific Corporation | Sheath for tissue spectroscopy |
US6185443B1 (en) | 1997-09-29 | 2001-02-06 | Boston Scientific Corporation | Visible display for an interventional device |
US6238348B1 (en) | 1997-07-22 | 2001-05-29 | Scimed Life Systems, Inc. | Miniature spectrometer system and method |
US6324418B1 (en) | 1997-09-29 | 2001-11-27 | Boston Scientific Corporation | Portable tissue spectroscopy apparatus and method |
US6436127B1 (en) * | 1997-10-08 | 2002-08-20 | The General Hospital Corporation | Phototherapy methods and systems |
CN1282230A (en) * | 1997-10-21 | 2001-01-31 | 加利福尼亚大学董事会 | Photoacoustic removal for occlusions from blood vessels |
US6289229B1 (en) | 1998-01-20 | 2001-09-11 | Scimed Life Systems, Inc. | Readable probe array for in vivo use |
AU6417599A (en) * | 1998-10-08 | 2000-04-26 | University Of Kentucky Research Foundation, The | Methods and apparatus for (in vivo) identification and characterization of vulnerable atherosclerotic plaques |
US6228076B1 (en) * | 1999-01-09 | 2001-05-08 | Intraluminal Therapeutics, Inc. | System and method for controlling tissue ablation |
US7277744B2 (en) * | 1999-03-22 | 2007-10-02 | Schaefer Allan L | Early detection of inflammation and infection using infrared thermography |
US6330058B1 (en) | 1999-04-14 | 2001-12-11 | University Of South Florida | Spectrophotometric method and apparatus for blood typing |
WO2000068683A1 (en) * | 1999-05-10 | 2000-11-16 | Tomoya Sato | Method and apparatus for determining the type and/or condition of disease and method and apparatus for screening drug |
US6424859B2 (en) * | 1999-06-17 | 2002-07-23 | Michael Jackson | Diagnosis of rheumatoid arthritis in vivo using a novel spectroscopic approach |
US7426409B2 (en) * | 1999-06-25 | 2008-09-16 | Board Of Regents, The University Of Texas System | Method and apparatus for detecting vulnerable atherosclerotic plaque |
US6445939B1 (en) | 1999-08-09 | 2002-09-03 | Lightlab Imaging, Llc | Ultra-small optical probes, imaging optics, and methods for using same |
US6577884B1 (en) | 2000-06-19 | 2003-06-10 | The General Hospital Corporation | Detection of stroke events using diffuse optical tomagraphy |
JP2004500197A (en) | 2000-02-08 | 2004-01-08 | コーネル リサーチ ファンデーション インコーポレーテッド | Multiphoton excitation for fluorescence spectroscopy through optical fibers |
US6934576B2 (en) | 2000-05-12 | 2005-08-23 | Hospital For Special Surgery | Determination of the ultrastructure of connective tissue by an infrared fiber-optic spectroscopic probe |
EP1434522B1 (en) * | 2000-10-30 | 2010-01-13 | The General Hospital Corporation | Optical systems for tissue analysis |
EP1347731B1 (en) * | 2000-11-02 | 2007-04-25 | Cornell Research Foundation, Inc. | In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease |
US9295391B1 (en) | 2000-11-10 | 2016-03-29 | The General Hospital Corporation | Spectrally encoded miniature endoscopic imaging probe |
US6625376B2 (en) | 2001-02-09 | 2003-09-23 | Sci Systems, Inc. | Fiber-optic cable terminal connector and alignment device and method |
US6898451B2 (en) * | 2001-03-21 | 2005-05-24 | Minformed, L.L.C. | Non-invasive blood analyte measuring system and method utilizing optical absorption |
WO2002088684A1 (en) * | 2001-04-30 | 2002-11-07 | The General Hospital Corporation | Method and apparatus for improving image clarity and sensitivity in optical coherence tomography using dynamic feedback to control focal properties and coherence gating |
AT503309B1 (en) * | 2001-05-01 | 2011-08-15 | Gen Hospital Corp | DEVICE FOR DETERMINING ATHEROSCLEROTIC BEARING BY MEASURING OPTICAL TISSUE PROPERTIES |
IL158664A0 (en) | 2001-05-03 | 2004-05-12 | Adanced Light Technology Llc | Differential photochemical and photomechanical processing |
WO2002090906A2 (en) * | 2001-05-10 | 2002-11-14 | Hospital For Special Surgery | Utilization of an infrared probe to discriminate between materials |
US6701181B2 (en) * | 2001-05-31 | 2004-03-02 | Infraredx, Inc. | Multi-path optical catheter |
DE60219627T2 (en) * | 2001-06-04 | 2008-02-07 | The General Hospital Corp., Boston | IDENTIFICATION AND THERAPY OF SENSITIVE PLAQUE WITH PHOTODYNAMIC COMPOUNDS |
US7992573B2 (en) * | 2001-06-19 | 2011-08-09 | The Trustees Of The University Of Pennsylvania | Optically guided system for precise placement of a medical catheter in a patient |
CA2451669A1 (en) | 2001-06-19 | 2002-12-27 | The Trustees Of The University Of Pennsylvania | Optical guidance system for invasive catheter placement |
US20030087456A1 (en) * | 2001-10-08 | 2003-05-08 | Jones Howland D.T. | Within-sample variance classification of samples |
US6980299B1 (en) | 2001-10-16 | 2005-12-27 | General Hospital Corporation | Systems and methods for imaging a sample |
US6648904B2 (en) * | 2001-11-29 | 2003-11-18 | Palomar Medical Technologies, Inc. | Method and apparatus for controlling the temperature of a surface |
JP2005530128A (en) * | 2002-01-11 | 2005-10-06 | ザ・ジェネラル・ホスピタル・コーポレイション | Apparatus for OCT imaging using axial line focus to improve resolution and depth regions |
US7355716B2 (en) * | 2002-01-24 | 2008-04-08 | The General Hospital Corporation | Apparatus and method for ranging and noise reduction of low coherence interferometry LCI and optical coherence tomography OCT signals by parallel detection of spectral bands |
US20110201924A1 (en) * | 2002-04-30 | 2011-08-18 | The General Hospital Corporation | Method and Apparatus for Improving Image Clarity and Sensitivity in Optical Tomography Using Dynamic Feedback to Control Focal Properties and Coherence Gating |
US20080177359A1 (en) * | 2002-05-03 | 2008-07-24 | Advanced Light Technology, Llc. | Differential photochemical and photomechanical processing |
US20040073132A1 (en) * | 2002-05-07 | 2004-04-15 | Tracy Maahs | Systems and methods for detecting vulnerable plaque |
US7672713B2 (en) * | 2002-06-19 | 2010-03-02 | Infraredx, Inc. | Multi-channel catheter tip |
WO2004000098A2 (en) | 2002-06-19 | 2003-12-31 | Palomar Medical Technologies, Inc. | Method and apparatus for treatment of cutaneous and subcutaneous conditions |
US7486985B2 (en) * | 2002-08-05 | 2009-02-03 | Infraredx, Inc. | Near-infrared spectroscopic analysis of blood vessel walls |
AU2003258062A1 (en) * | 2002-08-05 | 2004-02-23 | Infraredx, Inc. | Near-infrared spectroscopic analysis of blood vessel walls |
US7689268B2 (en) * | 2002-08-05 | 2010-03-30 | Infraredx, Inc. | Spectroscopic unwanted signal filters for discrimination of vulnerable plaque and method therefor |
US6999807B2 (en) * | 2003-01-23 | 2006-02-14 | Scimed Life Systems, Inc. | pH measuring balloon |
US7643153B2 (en) * | 2003-01-24 | 2010-01-05 | The General Hospital Corporation | Apparatus and method for ranging and noise reduction of low coherence interferometry LCI and optical coherence tomography OCT signals by parallel detection of spectral bands |
US7567349B2 (en) | 2003-03-31 | 2009-07-28 | The General Hospital Corporation | Speckle reduction in optical coherence tomography by path length encoded angular compounding |
CA2514189A1 (en) * | 2003-01-24 | 2004-08-12 | The General Hospital Corporation | System and method for identifying tissue using low-coherence interferometry |
WO2004075782A2 (en) * | 2003-02-26 | 2004-09-10 | Alfred, E. Mann Institute For Biomedical Engineering At The University Of Southern California | An implantable device with sensors for differential monitoring of internal condition |
US20110040295A1 (en) * | 2003-02-28 | 2011-02-17 | Photometics, Inc. | Cancer treatment using selective photo-apoptosis |
US7354433B2 (en) * | 2003-02-28 | 2008-04-08 | Advanced Light Technologies, Llc | Disinfection, destruction of neoplastic growth, and sterilization by differential absorption of electromagnetic energy |
KR20130138867A (en) | 2003-06-06 | 2013-12-19 | 더 제너럴 하스피탈 코포레이션 | Process and apparatus for a wavelength tunning source |
US20050119587A1 (en) * | 2003-07-01 | 2005-06-02 | University Of Michigan | Method and apparatus for evaluating connective tissue conditions |
US8417322B2 (en) | 2003-07-01 | 2013-04-09 | Regents Of The University Of Michigan | Method and apparatus for diagnosing bone tissue conditions |
AU2004297876A1 (en) * | 2003-08-19 | 2005-06-23 | Cornell Research Foundation, Inc. | Optical fiber delivery and collection system for biological applications such as multiphoton microscopy, spectroscopy, and endoscopy |
CN103181754A (en) | 2003-10-27 | 2013-07-03 | 通用医疗公司 | Method and apparatus for performing optical imaging using frequency-domain interferometry |
WO2005054780A1 (en) * | 2003-11-28 | 2005-06-16 | The General Hospital Corporation | Method and apparatus for three-dimensional spectrally encoded imaging |
WO2005059510A2 (en) * | 2003-12-11 | 2005-06-30 | The Regents Of The University Of California | Catheter-based mid-infrared reflectance and reflectance generated absorption spectroscopy |
WO2005117534A2 (en) | 2004-05-29 | 2005-12-15 | The General Hospital Corporation | Process, system and software arrangement for a chromatic dispersion compensation using reflective layers in optical coherence tomography (oct) imaging |
US7447408B2 (en) * | 2004-07-02 | 2008-11-04 | The General Hospital Corproation | Imaging system and related techniques |
US8081316B2 (en) | 2004-08-06 | 2011-12-20 | The General Hospital Corporation | Process, system and software arrangement for determining at least one location in a sample using an optical coherence tomography |
KR20120062944A (en) | 2004-08-24 | 2012-06-14 | 더 제너럴 하스피탈 코포레이션 | Method and apparatus for imaging of vessel segments |
EP1793730B1 (en) * | 2004-08-24 | 2011-12-28 | The General Hospital Corporation | Process, system and software arrangement for determining elastic modulus |
KR101269455B1 (en) | 2004-09-10 | 2013-05-30 | 더 제너럴 하스피탈 코포레이션 | System and method for optical coherence imaging |
JP4997112B2 (en) | 2004-09-29 | 2012-08-08 | ザ ジェネラル ホスピタル コーポレイション | Apparatus for transmitting at least one electromagnetic radiation and method of manufacturing the same |
EP2272424A1 (en) * | 2004-10-29 | 2011-01-12 | The General Hospital Corporation | Polarisation-sensitive optical coherence tomography |
JP5623692B2 (en) * | 2004-11-02 | 2014-11-12 | ザ ジェネラル ホスピタル コーポレイション | Optical fiber rotator, optical system and method for sample imaging |
US20080039715A1 (en) * | 2004-11-04 | 2008-02-14 | Wilson David F | Three-dimensional optical guidance for catheter placement |
US10413188B2 (en) | 2004-11-17 | 2019-09-17 | Lawrence Livermore National Security, Llc | Assessment of tissue or lesion depth using temporally resolved light scattering spectroscopy |
US20060229515A1 (en) * | 2004-11-17 | 2006-10-12 | The Regents Of The University Of California | Fiber optic evaluation of tissue modification |
US7995210B2 (en) * | 2004-11-24 | 2011-08-09 | The General Hospital Corporation | Devices and arrangements for performing coherence range imaging using a common path interferometer |
EP1816949A1 (en) | 2004-11-29 | 2007-08-15 | The General Hospital Corporation | Arrangements, devices, endoscopes, catheters and methods for performing optical imaging by simultaneously illuminating and detecting multiple points on a sample |
US7856985B2 (en) | 2005-04-22 | 2010-12-28 | Cynosure, Inc. | Method of treatment body tissue using a non-uniform laser beam |
JP2008538612A (en) * | 2005-04-22 | 2008-10-30 | ザ ジェネラル ホスピタル コーポレイション | Configuration, system, and method capable of providing spectral domain polarization sensitive optical coherence tomography |
EP1875436B1 (en) | 2005-04-28 | 2009-12-09 | The General Hospital Corporation | Evaluation of image features of an anatomical structure in optical coherence tomography images |
WO2006124860A1 (en) * | 2005-05-13 | 2006-11-23 | The General Hospital Corporation | Arrangements, systems and methods capable of providing spectral-domain optical coherence reflectometry for a sensitive detection of chemical and biological sample |
US20060262903A1 (en) * | 2005-05-20 | 2006-11-23 | Diebold Roger M | Method and apparatus for photothermal modification of x-ray images |
WO2006130797A2 (en) * | 2005-05-31 | 2006-12-07 | The General Hospital Corporation | Spectral encoding heterodyne interferometry techniques for imaging |
JP5702049B2 (en) * | 2005-06-01 | 2015-04-15 | ザ ジェネラル ホスピタル コーポレイション | Apparatus, method and system for performing phase resolved optical frequency domain imaging |
ES2354287T3 (en) * | 2005-08-09 | 2011-03-11 | The General Hospital Corporation | APPARATUS AND METHOD FOR PERFORMING A DEMODULATION IN QUADRATURE BY POLARIZATION IN OPTICAL COHERENCE TOMOGRAPHY. |
US7729749B2 (en) * | 2005-09-01 | 2010-06-01 | The Regents Of The University Of Michigan | Method and apparatus for evaluating connective tissue conditions |
US8050734B2 (en) * | 2005-09-07 | 2011-11-01 | General Electric Company | Method and system for performing patient specific analysis of disease relevant changes of a disease in an anatomical structure |
US8954134B2 (en) * | 2005-09-13 | 2015-02-10 | Children's Medical Center Corporation | Light-guided transluminal catheter |
US20070073160A1 (en) | 2005-09-13 | 2007-03-29 | Children's Medical Center Corporation | Light-guided transluminal catheter |
JP6046325B2 (en) * | 2005-09-29 | 2016-12-14 | ザ ジェネラル ホスピタル コーポレイション | Method and apparatus for the observation and analysis of one or more biological samples with progressively increased resolution |
US7889348B2 (en) * | 2005-10-14 | 2011-02-15 | The General Hospital Corporation | Arrangements and methods for facilitating photoluminescence imaging |
WO2007082228A1 (en) * | 2006-01-10 | 2007-07-19 | The General Hospital Corporation | Systems and methods for generating data based on one or more spectrally-encoded endoscopy techniques |
WO2007084945A1 (en) * | 2006-01-19 | 2007-07-26 | The General Hospital Corporation | Systems and methods for performing rapid fluorescense lifetime, excitation and emission spectral measurements |
CN104257348A (en) | 2006-01-19 | 2015-01-07 | 通用医疗公司 | Methods And Systems For Optical Imaging Of Epithelial Luminal Organs By Beam Scanning Thereof |
WO2007084903A2 (en) | 2006-01-19 | 2007-07-26 | The General Hospital Corporation | Apparatus for obtaining information for a structure using spectrally-encoded endoscopy techniques and method for producing one or more optical arrangements |
US20070171430A1 (en) * | 2006-01-20 | 2007-07-26 | The General Hospital Corporation | Systems and methods for providing mirror tunnel micropscopy |
US20070171433A1 (en) * | 2006-01-20 | 2007-07-26 | The General Hospital Corporation | Systems and processes for providing endogenous molecular imaging with mid-infrared light |
WO2007149601A2 (en) * | 2006-02-01 | 2007-12-27 | The General Hospital Corporation | Apparatus for controlling at least one of at least two sections of at least one fiber |
JP5524487B2 (en) * | 2006-02-01 | 2014-06-18 | ザ ジェネラル ホスピタル コーポレイション | A method and system for emitting electromagnetic radiation to at least a portion of a sample using a conformal laser treatment procedure. |
EP1986545A2 (en) * | 2006-02-01 | 2008-11-05 | The General Hospital Corporation | Apparatus for applying a plurality of electro-magnetic radiations to a sample |
EP1988825B1 (en) | 2006-02-08 | 2016-12-21 | The General Hospital Corporation | Arrangements and systems for obtaining information associated with an anatomical sample using optical microscopy |
WO2007101026A2 (en) | 2006-02-24 | 2007-09-07 | The General Hospital Corporation | Methods and systems for performing angle-resolved fourier-domain optical coherence tomography |
EP1991313A2 (en) * | 2006-03-01 | 2008-11-19 | The General Hospital Corporation | System and method for providing cell specific laser therapy of atherosclerotic plaques by targeting light absorbers in macrophages |
WO2007109540A2 (en) * | 2006-03-17 | 2007-09-27 | The General Hospital Corporation | Arrangement, method and computer-accessible medium for identifying characteristics of at least a portion of a blood vessel contained within a tissue using spectral domain low coherence interferometry |
CN101466298B (en) * | 2006-04-05 | 2011-08-31 | 通用医疗公司 | Methods arrangements and systems for polarization-sensitive optical frequency domain imaging of a sample |
EP3150110B1 (en) * | 2006-05-10 | 2020-09-02 | The General Hospital Corporation | Processes, arrangements and systems for providing frequency domain imaging of a sample |
WO2007133964A2 (en) * | 2006-05-12 | 2007-11-22 | The General Hospital Corporation | Processes, arrangements and systems for providing a fiber layer thickness map based on optical coherence tomography images |
EP2028996A2 (en) * | 2006-05-30 | 2009-03-04 | Koninklijke Philips Electronics N.V. | Apparatus for depth-resolved measurements of properties of tissue |
US20100165335A1 (en) * | 2006-08-01 | 2010-07-01 | The General Hospital Corporation | Systems and methods for receiving and/or analyzing information associated with electro-magnetic radiation |
US7586957B2 (en) | 2006-08-02 | 2009-09-08 | Cynosure, Inc | Picosecond laser apparatus and methods for its operation and use |
JP2010501877A (en) * | 2006-08-25 | 2010-01-21 | ザ ジェネラル ホスピタル コーポレイション | Apparatus and method for improving optical coherence tomography imaging capabilities using volumetric filtering techniques |
WO2008033909A2 (en) * | 2006-09-12 | 2008-03-20 | The General Hospital Corporation | Apparatus, probe and method for providing depth assessment in an anatomical structure |
WO2008049118A2 (en) | 2006-10-19 | 2008-04-24 | The General Hospital Corporation | Apparatus and method for obtaining and providing imaging information associated with at least one portion of a sample and effecting such portion(s) |
EP2104968A1 (en) * | 2007-01-19 | 2009-09-30 | The General Hospital Corporation | Rotating disk reflection for fast wavelength scanning of dispersed broadband light |
US20080206804A1 (en) * | 2007-01-19 | 2008-08-28 | The General Hospital Corporation | Arrangements and methods for multidimensional multiplexed luminescence imaging and diagnosis |
US7911621B2 (en) | 2007-01-19 | 2011-03-22 | The General Hospital Corporation | Apparatus and method for controlling ranging depth in optical frequency domain imaging |
US20080234567A1 (en) * | 2007-03-19 | 2008-09-25 | The General Hospital Corporation | Apparatus and method for providing a noninvasive diagnosis of internal bleeding |
US20080234586A1 (en) * | 2007-03-19 | 2008-09-25 | The General Hospital Corporation | System and method for providing noninvasive diagnosis of compartment syndrome using exemplary laser speckle imaging procedure |
WO2008118781A2 (en) * | 2007-03-23 | 2008-10-02 | The General Hospital Corporation | Methods, arrangements and apparatus for utilizing a wavelength-swept laser using angular scanning and dispersion procedures |
US10534129B2 (en) * | 2007-03-30 | 2020-01-14 | The General Hospital Corporation | System and method providing intracoronary laser speckle imaging for the detection of vulnerable plaque |
WO2008131082A1 (en) * | 2007-04-17 | 2008-10-30 | The General Hospital Corporation | Apparatus and methods for measuring vibrations using spectrally-encoded endoscopy techniques |
WO2008137637A2 (en) | 2007-05-04 | 2008-11-13 | The General Hospital Corporation | Methods, arrangements and systems for obtaining information associated with a sample using brillouin microscopy |
KR20100029235A (en) * | 2007-06-08 | 2010-03-16 | 싸이노슈어, 인코포레이티드 | Surgical waveguide |
WO2009018456A2 (en) * | 2007-07-31 | 2009-02-05 | The General Hospital Corporation | Systems and methods for providing beam scan patterns for high speed doppler optical frequency domain imaging |
JP5536650B2 (en) * | 2007-08-31 | 2014-07-02 | ザ ジェネラル ホスピタル コーポレイション | System and method for self-interfering fluorescence microscopy and associated computer-accessible media |
WO2009036453A1 (en) * | 2007-09-15 | 2009-03-19 | The General Hospital Corporation | Apparatus, computer-accessible medium and method for measuring chemical and/or molecular compositions of coronary atherosclerotic plaques in anatomical structures |
US7933021B2 (en) * | 2007-10-30 | 2011-04-26 | The General Hospital Corporation | System and method for cladding mode detection |
US20090225324A1 (en) * | 2008-01-17 | 2009-09-10 | The General Hospital Corporation | Apparatus for providing endoscopic high-speed optical coherence tomography |
US9332942B2 (en) * | 2008-01-28 | 2016-05-10 | The General Hospital Corporation | Systems, processes and computer-accessible medium for providing hybrid flourescence and optical coherence tomography imaging |
US11123047B2 (en) | 2008-01-28 | 2021-09-21 | The General Hospital Corporation | Hybrid systems and methods for multi-modal acquisition of intravascular imaging data and counteracting the effects of signal absorption in blood |
MY179050A (en) | 2008-04-04 | 2020-10-26 | Colgate Palmolive Co | Analysis of substrates having agents deposited thereon |
EP2274572A4 (en) | 2008-05-07 | 2013-08-28 | Gen Hospital Corp | System, method and computer-accessible medium for tracking vessel motion during three-dimensional coronary artery microscopy |
JP5795531B2 (en) * | 2008-06-20 | 2015-10-14 | ザ ジェネラル ホスピタル コーポレイション | Fused fiber optic coupler structure and method of using the same |
JP5667051B2 (en) * | 2008-07-14 | 2015-02-12 | ザ ジェネラル ホスピタル コーポレイション | Equipment for color endoscopy |
EP3330696B1 (en) | 2008-12-10 | 2023-07-12 | The General Hospital Corporation | Systems, apparatus and methods for extending imaging depth range of optical coherence tomography through optical sub-sampling |
WO2010090837A2 (en) * | 2009-01-20 | 2010-08-12 | The General Hospital Corporation | Endoscopic biopsy apparatus, system and method |
JP2012515930A (en) * | 2009-01-26 | 2012-07-12 | ザ ジェネラル ホスピタル コーポレーション | System, method and computer-accessible medium for providing a wide-field super-resolution microscope |
WO2010091190A2 (en) * | 2009-02-04 | 2010-08-12 | The General Hospital Corporation | Apparatus and method for utilization of a high-speed optical wavelength tuning source |
US9351642B2 (en) | 2009-03-12 | 2016-05-31 | The General Hospital Corporation | Non-contact optical system, computer-accessible medium and method for measurement at least one mechanical property of tissue using coherent speckle technique(s) |
RU2011150518A (en) * | 2009-05-13 | 2013-06-20 | Сумитомо Электрик Индастриз, Лтд. | DEVICE FOR ANALYSIS OF THE INTERNAL WALL OF A BLOOD VESSEL AND METHOD OF ANALYSIS OF THE INTERNAL WALL OF A BLOOD VESSEL |
US9002439B2 (en) | 2009-05-13 | 2015-04-07 | Sumitomo Electric Industries, Ltd. | Blood vessel wall analyzing device and blood vessel wall analyzing method |
US11490826B2 (en) | 2009-07-14 | 2022-11-08 | The General Hospital Corporation | Apparatus, systems and methods for measuring flow and pressure within a vessel |
EP2485641A4 (en) * | 2009-10-06 | 2015-10-14 | Gen Hospital Corp | Apparatus and methods for imaging particular cells including eosinophils |
EP2509488A4 (en) * | 2009-12-08 | 2014-04-09 | Gen Hospital Corp | Methods and arrangements for analysis, diagnosis, and treatment monitoring of vocal folds by optical coherence tomography |
EP2522269B1 (en) * | 2010-01-08 | 2016-07-27 | Konica Minolta Advanced Layers, Inc. | Probe |
US20110184310A1 (en) * | 2010-01-27 | 2011-07-28 | Joe Denton Brown | Method of heating a shape memory alloy of a surgical instrument |
US8804126B2 (en) * | 2010-03-05 | 2014-08-12 | The General Hospital Corporation | Systems, methods and computer-accessible medium which provide microscopic images of at least one anatomical structure at a particular resolution |
US20130137134A1 (en) * | 2010-03-29 | 2013-05-30 | Ben Gurion University Of The Negev Research And Development Authority | Method and system for detecting and monitoring hematological cancer |
US9069130B2 (en) | 2010-05-03 | 2015-06-30 | The General Hospital Corporation | Apparatus, method and system for generating optical radiation from biological gain media |
EP2575598A2 (en) | 2010-05-25 | 2013-04-10 | The General Hospital Corporation | Apparatus, systems, methods and computer-accessible medium for spectral analysis of optical coherence tomography images |
EP2575597B1 (en) | 2010-05-25 | 2022-05-04 | The General Hospital Corporation | Apparatus for providing optical imaging of structures and compositions |
WO2011151825A2 (en) | 2010-06-01 | 2011-12-08 | Todos Medical Ltd. | Diagnosis of cancer |
US10285568B2 (en) | 2010-06-03 | 2019-05-14 | The General Hospital Corporation | Apparatus and method for devices for imaging structures in or at one or more luminal organs |
US9510758B2 (en) | 2010-10-27 | 2016-12-06 | The General Hospital Corporation | Apparatus, systems and methods for measuring blood pressure within at least one vessel |
WO2012149175A1 (en) | 2011-04-29 | 2012-11-01 | The General Hospital Corporation | Means for determining depth-resolved physical and/or optical properties of scattering media |
US9719937B2 (en) | 2011-05-11 | 2017-08-01 | Todos Medical Ltd. | Diagnosis of cancer |
US9330092B2 (en) | 2011-07-19 | 2016-05-03 | The General Hospital Corporation | Systems, methods, apparatus and computer-accessible-medium for providing polarization-mode dispersion compensation in optical coherence tomography |
WO2013029047A1 (en) | 2011-08-25 | 2013-02-28 | The General Hospital Corporation | Methods, systems, arrangements and computer-accessible medium for providing micro-optical coherence tomography procedures |
EP2769491A4 (en) | 2011-10-18 | 2015-07-22 | Gen Hospital Corp | Apparatus and methods for producing and/or providing recirculating optical delay(s) |
US9629528B2 (en) | 2012-03-30 | 2017-04-25 | The General Hospital Corporation | Imaging system, method and distal attachment for multidirectional field of view endoscopy |
KR102342629B1 (en) | 2012-04-18 | 2021-12-22 | 싸이노슈어, 엘엘씨 | Picosecond laser apparatus and methods for treating target tissues with same |
WO2013177154A1 (en) | 2012-05-21 | 2013-11-28 | The General Hospital Corporation | Apparatus, device and method for capsule microscopy |
JP6227652B2 (en) | 2012-08-22 | 2017-11-08 | ザ ジェネラル ホスピタル コーポレイション | System, method, and computer-accessible medium for fabricating a miniature endoscope using soft lithography |
WO2014120791A1 (en) | 2013-01-29 | 2014-08-07 | The General Hospital Corporation | Apparatus, systems and methods for providing information regarding the aortic valve |
WO2014121082A1 (en) | 2013-02-01 | 2014-08-07 | The General Hospital Corporation | Objective lens arrangement for confocal endomicroscopy |
US9592027B2 (en) | 2013-03-14 | 2017-03-14 | Volcano Corporation | System and method of adventitial tissue characterization |
EP2967491B1 (en) | 2013-03-15 | 2022-05-11 | The General Hospital Corporation | A transesophageal endoscopic system for determining a mixed venous oxygen saturation of a pulmonary artery |
US10285757B2 (en) | 2013-03-15 | 2019-05-14 | Cynosure, Llc | Picosecond optical radiation systems and methods of use |
WO2014186353A1 (en) | 2013-05-13 | 2014-11-20 | The General Hospital Corporation | Detecting self-interefering fluorescence phase and amplitude |
US9804145B2 (en) | 2013-05-28 | 2017-10-31 | Todos Medical Ltd. | Infrared analysis of benign tumors |
WO2015009932A1 (en) | 2013-07-19 | 2015-01-22 | The General Hospital Corporation | Imaging apparatus and method which utilizes multidirectional field of view endoscopy |
EP3021735A4 (en) | 2013-07-19 | 2017-04-19 | The General Hospital Corporation | Determining eye motion by imaging retina. with feedback |
ES2893237T3 (en) | 2013-07-26 | 2022-02-08 | Massachusetts Gen Hospital | Apparatus with a laser arrangement using optical scattering for applications in optical coherence tomography in the Fourier domain |
US9733460B2 (en) | 2014-01-08 | 2017-08-15 | The General Hospital Corporation | Method and apparatus for microscopic imaging |
WO2015116986A2 (en) | 2014-01-31 | 2015-08-06 | The General Hospital Corporation | System and method for facilitating manual and/or automatic volumetric imaging with real-time tension or force feedback using a tethered imaging device |
WO2015153982A1 (en) | 2014-04-04 | 2015-10-08 | The General Hospital Corporation | Apparatus and method for controlling propagation and/or transmission of electromagnetic radiation in flexible waveguide(s) |
EP3171766B1 (en) * | 2014-07-25 | 2021-12-29 | The General Hospital Corporation | Apparatus for in vivo imaging and diagnosis |
KR102627248B1 (en) | 2018-02-26 | 2024-01-19 | 싸이노슈어, 엘엘씨 | Q-switched cavity dumping subnanosecond laser |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3769963A (en) * | 1972-03-31 | 1973-11-06 | L Goldman | Instrument for performing laser micro-surgery and diagnostic transillumination of living human tissue |
US4281645A (en) * | 1977-06-28 | 1981-08-04 | Duke University, Inc. | Method and apparatus for monitoring metabolism in body organs |
JPS5552750A (en) * | 1978-10-12 | 1980-04-17 | Mochida Pharm Co Ltd | Laser knife* which can be detected* of tumor portion |
US4515165A (en) * | 1980-02-04 | 1985-05-07 | Energy Conversion Devices, Inc. | Apparatus and method for detecting tumors |
FR2521727A2 (en) * | 1981-03-25 | 1983-08-19 | Cilas | DEVICE FOR MEASURING THE STATE OF OXYDO-REDUCTION OF A LIVING ORGAN IN SITU |
US4509522A (en) * | 1981-12-15 | 1985-04-09 | The United States Of America As Represented By The Secretary Of The Navy | Infrared optical measurement of blood gas concentrations and fiber optic catheter |
US4765330A (en) * | 1983-08-15 | 1988-08-23 | Bert Bach | Method and apparatus for removal of plaque from blood vessels |
US4641650A (en) * | 1985-03-11 | 1987-02-10 | Mcm Laboratories, Inc. | Probe-and-fire lasers |
US4718417A (en) * | 1985-03-22 | 1988-01-12 | Massachusetts Institute Of Technology | Visible fluorescence spectral diagnostic for laser angiosurgery |
US4655225A (en) * | 1985-04-18 | 1987-04-07 | Kurabo Industries Ltd. | Spectrophotometric method and apparatus for the non-invasive |
DE3686621T2 (en) * | 1985-07-31 | 1993-02-25 | Bard Inc C R | INFRARED LASER CATHETER DEVICE. |
US4800279A (en) * | 1985-09-13 | 1989-01-24 | Indiana University Foundation | Methods and devices for near-infrared evaluation of physical properties of samples |
US4854315A (en) * | 1987-06-25 | 1989-08-08 | Stack Richard S | Laser catheter |
US5036853A (en) * | 1988-08-26 | 1991-08-06 | Polartechnics Ltd. | Physiological probe |
US4975581A (en) * | 1989-06-21 | 1990-12-04 | University Of New Mexico | Method of and apparatus for determining the similarity of a biological analyte from a model constructed from known biological fluids |
-
1990
- 1990-07-16 US US07/568,452 patent/US5197470A/en not_active Expired - Lifetime
-
1991
- 1991-02-08 CA CA002036031A patent/CA2036031A1/en not_active Abandoned
- 1991-07-11 EP EP19910201807 patent/EP0467459A3/en not_active Withdrawn
- 1991-07-15 JP JP17410691A patent/JP3234249B2/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5733507A (en) * | 1995-06-07 | 1998-03-31 | Inphocyte, Inc. | Biological cell sample holder for use in infrared and/or Raman spectroscopy analysis holder |
US5848977A (en) * | 1996-02-16 | 1998-12-15 | Inphocyte, Inc. | Sample holder for cells |
Also Published As
Publication number | Publication date |
---|---|
JPH04241851A (en) | 1992-08-28 |
US5197470A (en) | 1993-03-30 |
EP0467459A2 (en) | 1992-01-22 |
EP0467459A3 (en) | 1992-07-01 |
JP3234249B2 (en) | 2001-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5197470A (en) | Near infrared diagnostic method and instrument | |
US5701902A (en) | Spectroscopic burn injury evaluation apparatus and method | |
Leon et al. | Human arterial surface fluorescence: atherosclerotic plaque identification and effects of laser atheroma ablation | |
US5562100A (en) | Method for laser induced fluorescence of tissue | |
US5345941A (en) | Contour mapping of spectral diagnostics | |
US5452723A (en) | Calibrated spectrographic imaging | |
US6690966B1 (en) | Methods of molecular spectroscopy to provide for the diagnosis of tissue | |
US5074306A (en) | Measurement of burn depth in skin | |
US4981138A (en) | Endoscopic fiberoptic fluorescence spectrometer | |
JP2739933B2 (en) | Fiber optic spectroscopy catheter | |
CA2283949A1 (en) | Methods and apparatus for detecting the rejection of transplanted tissue | |
JP2003111789A (en) | Probe for entoptic illumination and ophthalmic operating instrument | |
Bartorelli et al. | In vivo human atherosclerotic plaque recognition by laser-excited fluorescence spectroscopy | |
Morguet et al. | Autofluorescence spectroscopy using a XeCl excimer laser system for simultaneous plaque ablation and fluorescence excitation | |
WO1990005563A1 (en) | Method and apparatus for laser angioplasty | |
Bosshart et al. | Fluorescence spectroscopy for identification of atherosclerotic tissue | |
Strebel et al. | Excimer laser spectroscopy: Influence of tissue ablation on vessel wall fluorescence | |
Schwarzmaier et al. | Optical density of vascular tissue before and after 308-nm excimer laser irradiation | |
Kramer Jr et al. | Spectral diagnosis of human coronary artery: a clinical system for real-time analysis | |
Ye et al. | Decrease in total fluorescence from human arteries with increasing beta-carotene content | |
Yova et al. | Interpretation of diagnostic implications of fluorescence parameters for atherosclerosis in fibrous, calcified and normal arteries | |
Meirong et al. | Study of diagnosis criteria for pathological tissues by laser-induced fluorescence | |
Deckelbaum | Laser-induced arterial fluorescence spectroscopy | |
Ye et al. | Beta carotene decreases total fluorescence from human arteries | |
MacAulay et al. | Organ transplant tissue rejection: detection and staging by fluorescence spectroscopy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |